DA COSTA PEREIRA ROSA CARLA PATRÍCIA (PT)
CORDEIRO SIMÕES ANA VANESSA (PT)
RAMOS DAMIL JOÃO CARLOS (PT)
SILVA SERRA JOÃO PEDRO (PT)
ALMEIDA FERREIRA ANA LÚCIA (PT)
GOMES NEVES RITA ISABEL (PT)
MARQUES HOMEM E SOUSA DOS SANTOS SARA ALEXANDRA (PT)
WO2019243971A1 | 2019-12-26 | |||
WO2013060744A2 | 2013-05-02 | |||
WO2012025237A9 | 2013-02-14 | |||
WO2009001060A2 | 2008-12-31 | |||
WO2017001661A1 | 2017-01-05 |
EP1527050B1 | 2010-04-07 | |||
US20160113919A1 | 2016-04-28 | |||
US7868022B2 | 2011-01-11 | |||
US7989628B2 | 2011-08-02 |
COMAS ET AL., NAT. GENET., vol. 45, 2013, pages 1176 - 1182
WHO, WHO GLOBAL TUBERCULOSIS REPORT, 2017, pages 2017
HOAGLAND DT ET AL., ADV DRUG DELIV REV., vol. 102, 1 July 2016 (2016-07-01), pages 55 - 72
TANTRY, S. J. ET AL., MED. CHEM. COMMUN., vol. 7, 2016, pages 1022 - 1032
REDASANI, V.K. ET AL.: "Prodrug Design", 2015, ELSEVIER
PETER G. M. WUTS: "Greener's Protecting Groups in Organic synthesis", 2014, WILEY
CORY A. ET AL., CANCER COMMUN., vol. 3, no. 7, 1991, pages 207 - 212
PALOMINO JC ET AL., MYCOBACTERIUM TUBERCULOSIS ANTIMICROB. AGENTS CHEMOTHER., vol. 46, no. 8, 2002, pages 2720 - 2722
C L A I M S 1. Compound of general formula I or a pharmaceutically acceptable salt, hydrate, solvate, N-oxide, stereoisomer, diastereoisomer, enantiomer, atropisomer, polymorph or ester thereof: Formula I wherein R1, R2, R3 and ring A are independently selected from each other; Ring A is a substituted or unsubstituted ring selected from pyridin-2-yl, pyridin-3-yl, pyridin-4-yl, pyrazin-2-yl, 1H-pyrrolo[2,3-b]pyridine-5-yl, furan-2-yl, 6-methoxybenzo[d]thiazol-2-yl, thiophen- 2-yl, 3-pyridine 1-oxide, pyrimidin-2-yl or phenyl; R1 is selected from H, Halogen, C1-C6 alkoxy, or unsubstituted heteroaryl; R2 is selected from H or OH; R3 is selected from H, Halogen, C1-C6 alkoxy, or unsubstituted heteroaryl. 2. Compounds of the formula I according to claim 1, wherein Ring A is a substituted or unsubstituted ring selected from pyridin-2-yl, pyridin-3-yl, pyridin-4-yl, pyrazin-2-yl, 1H-pyrrolo[2,3-b]pyridine-5-yl, furan-2-yl, 6-methoxybenzo[d]thiazol-2-yl, thiophen- 2-yl, 3-pyridine 1-oxide, pyrimidin-2-yl or phenyl; R1 is selected from H, Cl, OCH3 or unsubstituted heteroaryl; R2 is selected from H or OH; R3 is selected from H, Cl, OCH3 or unsubstituted heteroaryl. 3. Compounds according to any of the claims 1 - 2, wherein R1, R2, R3, R4, R5 and R6 are independently selected from each other; R1 is selected from H, Cl, OCH3 or pyridine-4-yl; R2 is selected from H or OH; R3 is selected from H, Cl, OCH3 or pyridine-4-yl; R4 is selected from H, OCH3, CF3, OCF3, NO2 or NH2; R5 is selected from H, OCH3, CF3, OCF3, F, NO2 or OH; R6 is selected from H, OCH3, CF3 or OCF3. 4. Compound according to any of the claims 1 -2, wherein R1, R2, R3, R7, R8 are independently selected from each other; X, Y, Z and W are independently selected from C or N; R1 is selected from H, Cl, OCH3 or pyridine-4-yl; R2 is selected from H or OH; R3 is selected from H, Cl, OCH3 or pyridine-4-yl; R7 is selected from H, OCH3, CF3, NHCH3, NH2, Cl, piperidinyl, piperazinyl, morpholinyl, pyrrolidinyl, NH(CH2)OH or CH3; R8 is selected from H, F or OH. 5. Compounds according to any of the claims 1 -2, wherein Formula IV R1 is selected from H, Cl, OCH3 or pyridine-4-yl; R2 is selected from H or OH; R3 is selected from H, Cl, OCH3 or pyridine-4-yl; m is selected from 0 or 1; R9 is selected from H or tert-butyl carbamate. 6. Compounds according to any of the claims 1 -2, wherein Formula V R1 is selected from H, Cl, OCH3 or pyridine-4-yl; R2 is selected from H or OH; R3 is selected from H, Cl, OCH3 or pyridine-4-yl; X is C or N; K is S or O; R10 and R11 are selected from H or attached together with carbons to form 6- methoxybenzo[d]thiazol-2-yl. 7. Compound according to claim 3, wherein R3 is H or OCH3. 8. Compound according to claim 3, wherein R4 is H, OCH3 or CF3. 9. Compound according to claim 3, wherein R5 is selected from H, CF3, OCF3 or OH. 10. Compound according to claim 3, wherein R6 is selected from H, OCH3 or CF3. 11. Compound according to claim 4, wherein X is N. 12. Compound according to claim 4, wherein R1 is H, Cl, OCH3 or pyridine-4-yl. 13. Compound according to claim 4, wherein R3 is H, Cl, or OCH3. 14. Compound according to claim 4, wherein R7 is H, CF3, Cl, piperidinyl, piperazinyl, pyrrolidinyl or NH(CH2)OH. 15. Compound according to any of the previous claims, wherein the salt is a hydrochloride or a trifluoroacetate. 16. Compound according to any of the previous claims, wherein the compound is: 5-(1-(6-chloroquinolin-2-yl)piperidin-4-yl)-3-phenyl-1,2,4-oxadiazole; 5-(1-(6-chloroquinolin-2-yl)piperidin-4-yl)-3-(4-(trifluoromethoxy)phenyl)-1,2,4-oxadiazole; 5-(1-(8-methoxyquinolin-2-yl)piperidin-4-yl)-3-(4-(trifluoromethoxy)phenyl)-1,2,4-oxadiazole; 5-(1-(8-chloroquinolin-2-yl)piperidin-4-yl)-3-(4-(trifluoromethoxy)phenyl)-1,2,4-oxadiazole; 5-(1-(8-methoxyquinolin-2-yl)piperidin-4-yl)-3-(4-(trifluoromethyl)phenyl)-1,2,4-oxadiazole hydrochloride; 3-(3,5-dimethoxyphenyl)-5-(1-(8-methoxyquinolin-2-yl)piperidin-4-yl)-1,2,4-oxadiazole; 5-(1-(8-methoxyquinolin-2-yl)piperidin-4-yl)-3-(3-(trifluoromethyl)phenyl)-1,2,4-oxadiazole; 3-(3,5-bis(trifluoromethyl)phenyl)-5-(1-(8-methoxyquinolin-2-yl)piperidin-4-yl)-1,2,4-oxadiazole; 5-(1-(8-methoxyquinolin-2-yl)piperidin-4-yl)-3-(pyridin-4-yl)-1,2,4-oxadiazole; 5-(1-(8-methoxyquinolin-2-yl)piperidin-4-yl)-3-(pyridin-3-yl)-1,2,4-oxadiazole hydrochloride; 5-(1-(8-methoxyquinolin-2-yl)piperidin-4-yl)-3-(6-(trifluoromethyl)pyridin-3-yl)-1,2,4-oxadiazole; 3-(3-methoxyphenyl)-5-(1-(8-methoxyquinolin-2-yl)piperidin-4-yl)-1,2,4-oxadiazole hydrochloride; 5-(1-(8-methoxyquinolin-2-yl)piperidin-4-yl)-3-(3-(trifluoromethoxy)phenyl)-1,2,4-oxadiazole; 3-(4-methoxyphenyl)-5-(1-(8-methoxyquinolin-2-yl)piperidin-4-yl)-1,2,4-oxadiazole; 5-(1-(6-chloroquinolin-2-yl)piperidin-4-yl)-3-(pyridin-3-yl)-1,2,4-oxadiazole hydrochloride; 5-(1-(8-methoxyquinolin-2-yl)piperidin-4-yl)-3-(pyrazin-2-yl)-1,2,4-oxadiazole hydrochloride; 7-hydroxy-8-methoxy-2-(4-(3-(pyridin-3-yl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl)quinoline 1-oxide; 5-(1-(8-chloroquinolin-2-yl)piperidin-4-yl)-3-(pyridin-3-yl)-1,2,4-oxadiazole hydrochloride; 5-(1-(8-chloroquinolin-2-yl)piperidin-4-yl)-3-(4-fluorophenyl)-1,2,4-oxadiazole; 3-(pyridin-3-yl)-5-(1-(8-(pyridin-4-yl)quinolin-2-yl)piperidin-4-yl)-1,2,4-oxadiazole hydrochloride; 5-(1-(6-methoxyquinolin-2-yl)piperidin-4-yl)-3-(pyridin-3-yl)-1,2,4-oxadiazole; 5-(1-(6-methoxyquinolin-2-yl)piperidin-4-yl)-3-(4-(trifluoromethoxy)phenyl)-1,2,4-oxadiazole; 5-(1-(8-methoxyquinolin-2-yl)piperidin-4-yl)-3-(4-nitrophenyl)-1,2,4-oxadiazole; 4-(5-(1-(8-methoxyquinolin-2-yl)piperidin-4-yl)-1,2,4-oxadiazol-3-yl)phenol; 5-(1-(8-methoxyquinolin-2-yl)piperidin-4-yl)-3-(pyridin-2-yl)-1,2,4-oxadiazole hydrochloride; 3-(5-(1-(8-methoxyquinolin-2-yl)piperidin-4-yl)-1,2,4-oxadiazol-3-yl)pyridine 1-oxide; 3-(pyridin-3-yl)-5-(1-(6-(pyridin-4-yl)quinolin-2-yl)piperidin-4-yl)-1,2,4-oxadiazole; 5-(5-(1-(8-methoxyquinolin-2-yl)piperidin-4-yl)-1,2,4-oxadiazol-3-yl)-N-methylpyridin-2-amine; 5-(1-(8-methoxyquinolin-2-yl)piperidin-4-yl)-3-(3-nitrophenyl)-1,2,4-oxadiazole; 5-(5-(1-(8-methoxyquinolin-2-yl)piperidin-4-yl)-1,2,4-oxadiazol-3-yl)pyridin-2-amine hydrochloride; 3-(6-chloropyridin-3-yl)-5-(1-(8-methoxyquinolin-2-yl)piperidin-4-yl)-1,2,4-oxadiazole hydrochloride; 5-(1-(8-methoxyquinolin-2-yl)piperidin-4-yl)-3-(pyrimidin-2-yl)-1,2,4-oxadiazole; 5-(1-(8-methoxyquinolin-2-yl)piperidin-4-yl)-3-(6-(piperidin-1-yl)pyridin-3-yl)-1,2,4-oxadiazole; 5-(1-(8-methoxyquinolin-2-yl)piperidin-4-yl)-3-(6-(piperazin-1-yl)pyridin-3-yl)-1,2,4-oxadiazole; 2-((5-(5-(1-(8-methoxyquinolin-2-yl)piperidin-4-yl)-1,2,4-oxadiazol-3-yl)pyridin-2- yl)amino)ethan-1-ol hydrochloride; 5-(5-(1-(8-methoxyquinolin-2-yl)piperidin-4-yl)-1,2,4-oxadiazol-3-yl)pyridin-3-ol; 5-(1-(8-methoxyquinolin-2-yl)piperidin-4-yl)-3-(1H-pyrrolo[2,3-b]pyridin-5-yl)-1,2,4-oxadiazole; 3-(furan-2-yl)-5-(1-(8-methoxyquinolin-2-yl)piperidin-4-yl)-1,2,4-oxadiazole; 5-(1-(8-methoxyquinolin-2-yl)piperidin-4-yl)-3-(6-methylpyridin-3-yl)-1,2,4-oxadiazole; tert-butyl ((1-(5-(5-(1-(8-methoxyquinolin-2-yl)piperidin-4-yl)-1,2,4-oxadiazol-3-yl)pyridin-2- yl)piperidin-4-yl)methyl)carbamate; tert-butyl ((1-(5-(5-(1-(8-methoxyquinolin-2-yl)piperidin-4-yl)-1,2,4-oxadiazol-3-yl)pyridin-2- yl)pyrrolidin-3-yl)methyl)carbamate; (1-(5-(5-(1-(8-methoxyquinolin-2-yl)piperidin-4-yl)-1,2,4-oxadiazol-3-yl)pyridin-2-yl)pyrrolidin-3- yl)methanamine trifluoroacetate; (1-(5-(5-(1-(8-methoxyquinolin-2-yl)piperidin-4-yl)-1,2,4-oxadiazol-3-yl)pyridin-2-yl)piperidin-4- yl)methanamine trifluoroacetate; 3-(6-methoxybenzo[d]thiazol-2-yl)-5-(1-(8-methoxyquinolin-2-yl)piperidin-4-yl)-1,2,4-oxadiazole; 5-(1-(8-methoxyquinolin-2-yl)piperidin-4-yl)-3-(thiophen-2-yl)-1,2,4-oxadiazole; 4-(5-(5-(1-(8-methoxyquinolin-2-yl)piperidin-4-yl)-1,2,4-oxadiazol-3-yl)pyridin-2-yl)morpholine; 3-(5-(1-(8-methoxyquinolin-2-yl)piperidin-4-yl)-1,2,4-oxadiazol-3-yl)aniline hydrochloride; 3-(6-methoxypyridin-3-yl)-5-(1-(8-methoxyquinolin-2-yl)piperidin-4-yl)-1,2,4-oxadiazole; 3-(5-fluoropyridin-3-yl)-5-(1-(8-methoxyquinolin-2-yl)piperidin-4-yl)-1,2,4-oxadiazole; or 5-(1-(8-methoxyquinolin-2-yl)piperidin-4-yl)-3-(6-(pyrrolidin-1-yl)pyridin-3-yl)-1,2,4-oxadiazole hydrochloride. 17. Compound according to any of the previous claims, wherein the compound is selected from: 5-(1-(8-methoxyquinolin-2-yl)piperidin-4-yl)-3-(4-(trifluoromethoxy)phenyl)-1,2,4-oxadiazole; 5-(1-(8-methoxyquinolin-2-yl)piperidin-4-yl)-3-(4-(trifluoromethyl)phenyl)-1,2,4-oxadiazole hydrochloride; 3-(3,5-dimethoxyphenyl)-5-(1-(8-methoxyquinolin-2-yl)piperidin-4-yl)-1,2,4-oxadiazole; 5-(1-(8-methoxyquinolin-2-yl)piperidin-4-yl)-3-(3-(trifluoromethyl)phenyl)-1,2,4-oxadiazole; 5-(1-(8-methoxyquinolin-2-yl)piperidin-4-yl)-3-(pyridin-3-yl)-1,2,4-oxadiazole hydrochloride; 5-(1-(8-methoxyquinolin-2-yl)piperidin-4-yl)-3-(6-(trifluoromethyl)pyridin-3-yl)-1,2,4-oxadiazole; 5-(1-(8-chloroquinolin-2-yl)piperidin-4-yl)-3-(pyridin-3-yl)-1,2,4-oxadiazole hydrochloride; 5-(1-(6-methoxyquinolin-2-yl)piperidin-4-yl)-3-(pyridin-3-yl)-1,2,4-oxadiazole; 4-(5-(1-(8-methoxyquinolin-2-yl)piperidin-4-yl)-1,2,4-oxadiazol-3-yl)phenol; 3-(pyridin-3-yl)-5-(1-(6-(pyridin-4-yl)quinolin-2-yl)piperidin-4-yl)-1,2,4-oxadiazole; 3-(6-chloropyridin-3-yl)-5-(1-(8-methoxyquinolin-2-yl)piperidin-4-yl)-1,2,4-oxadiazole hydrochloride; 5-(1-(8-methoxyquinolin-2-yl)piperidin-4-yl)-3-(6-(piperidin-1-yl)pyridin-3-yl)-1,2,4-oxadiazole; 5-(1-(8-methoxyquinolin-2-yl)piperidin-4-yl)-3-(6-(piperazin-1-yl)pyridin-3-yl)-1,2,4-oxadiazole; 2-((5-(5-(1-(8-methoxyquinolin-2-yl)piperidin-4-yl)-1,2,4-oxadiazol-3-yl)pyridin-2- yl)amino)ethan-1-ol hydrochloride; or 5-(1-(8-methoxyquinolin-2-yl)piperidin-4-yl)-3-(6-(pyrrolidin-1-yl)pyridin-3-yl)-1,2,4-oxadiazole hydrochloride. 18. Compound according to any of the previous claims for use in medicine or veterinary. 19. Compound according to any of the previous claims for use in the treatment or prevention of tuberculosis. 20. Compound for use according to any of the previous claims 18-19 in combination with at least one anti-HIV agent, wherein the anti-HIV agent is selected from a HIV protease inhibitor, a HIV nucleoside reverse transcriptase inhibitor, a HIV non-nucleoside reverse transcriptase inhibitor, or a HIV integrase inhibitor. 21. Compound for use according to claim 18-20 in combination with at least a second tuberculosis drug, wherein the further tuberculosis drug is selected from the group of isoniazid, rifamycin and derivatives, pyrazinamide, ethambutol, cycloserine, ethionamide, streptomycin, amikacin, kanamycin, rifampin (rifampicin), aminoglycosides, capreomycin, p-aminosalicyclic acid, fluoroquinolones such as levofloxacin, moxafloxacin or gatifloxacin, or mixtures thereof. 22. Pharmaceutical composition comprising a compound according to any of the previous claims 1- 21 and a pharmaceutical acceptable excipient, wherein the compound is a therapeutically effective amount of a compound described in any of the previous claims or a pharmaceutically acceptable salt or solvate thereof. |
[00153] In an embodiment, preparation of intermediate 1 (tert-butyl 4-(3-phenyl-1,2,4-oxadiazol-5- yl)piperidine-1-carboxylate) was performed. Carbonyldiimidazole (CDI) (770 mg, 4.8 mmol) was added to a solution of 1-(tert-butoxycarbonyl)piperidine-4-carboxylic acid (1g, 4.3 mmol) in PhMe (10 ml) and the mixture was allowed to stir at room temperature for 2 hours. Benzamidoxime (650 mg, 4.8 mmol) was added and the resulting mixture was allowed to stir at room temperature and then at 110 ºC over a duration of 1.5 hours. The solvent was evaporated, the resulting residue was diluted with ethyl acetate (EtOAc) and water, the organic layer was separated, dried over anhydrous sodium sulphate, filtered, evaporated in vacuum and the resulting residue was dried over high vacuum at 40 ºC. The intermediate 1 was isolated as a colourless solid (900 mg, 62%). [00154] In an embodiment, preparation of intermediate 2 (3-phenyl-5-(piperidin-4-yl)-1,2,4-oxadiazole) was performed. TFA (2.7 ml) was added to a solution of intermediate 1 (880 mg, 2.6 mmol) in DCM (6.8 ml). The mixture was allowed to stir at room temperature for 1hour. The solvent was removed in vacuum and the resulting residue was suspended and triturated in diethyl ether. The product was separated by filtration and was dried in high vacuum at 40 ºC. The intermediate 2, was isolated as a colourless solid (850 mg, 70%). [00155] In an embodiment, preparation of compound 1 (5-(1-(6-chloroquinolin-2-yl)piperidin-4-yl)-3- phenyl-1,2,4-oxadiazole) was performed. DIPEA (4.3 ml) was added to a suspension of 2,6- dichloroquinoline (243.6 mg, 1.23 mmol) and Intermediate 2 (400 mg, 1.23 mmol) in 1-BuOH (8.3 ml) and the mixture was allowed to stir at 130 ºC over a duration of 20 hours. The solvent was evaporated, and the resulting residue was purified by column chromatography (silica gel, Petrol ether/EtOAc 4:1) in order to obtain compound 1 as an off-white solid (240 mg, 61%). [00156] HPLC-MS [M+H] + 391.12; MP: 130-135 ºC; 1 H NMR (400 MHz, CDCl 3 ) δ 8.12 – 8.04 (m, 2H), 7.81 (d, J = 9.2 Hz, 1H), 7.67 – 7.55 (m, 2H), 7.52-7.45 (m, 4H), 7.05 (d, J = 9.2 Hz, 1H), 4.55 (dt, J = 13.6, 4.0 Hz, 2H), 3.39 – 3.19 (m, 3H), 2.28 (dt, J = 12.4, 3.7 Hz, 2H), 2.14 – 1.98 (m, 2H); 13 C NMR (101 MHz, CDCl 3 ) δ 181.38, 168.28, 157.15, 146.35, 136.63, 131.16, 130.15, 128.84, 128.16, 127.54, 127.43, 126.81, 125.92, 12.55, 110.55, 44.65, 34.84, 29.05. [00157] In an embodiment, the method of synthesizing Compound 2 (5-(1-(6-chloroquinolin-2- yl)piperidin-4-yl)-3-(4-(trifluoromethoxy)phenyl)-1,2,4-oxad iazole) is as follows: [00158] In an embodiment, preparation of intermediate 3 (tert-butyl 4-(3-phenyl-1,2,4-oxadiazol-5- yl)piperidine-1-carboxylate) was performed. Carbonyldiimidazole (CDI) (770 mg, 4.8 mmol) was added to a solution of 1-(tert-butoxycarbonyl)piperidine-4-carboxylic acid (1g, 4.3 mmol) in PhMe (10 ml) and the mixture was allowed to stir at room temperature for 2 hours. Benzamidoxime (650 mg, 4.8 mmol) was added and the resulting mixture was allowed to stir at room temperature for 1 hour and at 110 ºC over a duration of 2 hours. The solvent was evaporated, the resulting residue was diluted with EtOAc and water, the organic layer was separated, dried over anhydrous sodium sulphate, filtered, evaporated in vacuum and the resulting residue was dried over high vacuum at 40 ºC. The intermediate 3 was isolated as a brown solid (1 g, 57%). [00159] In an embodiment, preparation of intermediate 4 (3-phenyl-5-(piperidin-4-yl)-1,2,4-oxadiazole trifluoroacetate) was performed. TFA (2.5 ml) was added to a solution of intermediate 3 (1 g, 2.4 mmol) in DCM (6.3 ml). The mixture was allowed to stir at room temperature for 1 hour. The solvent was removed in vacuum and the resulting residue was suspended and triturated in diethyl ether. The product was separated by filtration and was dried in high vacuum at 40 ºC. The intermediate 4, was isolated as a colourless solid (920 mg, 90%). [00160] In an embodiment, preparation of compound 2 (5-(1-(6-chloroquinolin-2-yl)piperidin-4-yl)-3-(4- (trifluoromethoxy)phenyl)-1,2,4-oxadiazole) was performed. DIPEA (2.3 ml) was added to a suspension of 2,6-dichloroquinoline (146 mg, 0.73 mmol) and Intermediate 4 (300 mg, 0.73 mmol) in 1-BuOH (4.4 ml) and the mixture was allowed to stir at 130 ºC over a duration of 20 hours. The solvent was evaporated, and the resulting residue was purified by column chromatography (silica gel, Petrol ether/EtOAc 4:1) in order to obtain compound 2 as an off-white solid (190 mg, 55%). [00161] HPLC-MS [M+H] + 475.06; MP: 122-126 ºC; 1 H NMR (400 MHz, CDCl 3 ) δ 8.16 – 8.08 (m, 2H), 7.82 (d, J = 9.2 Hz, 1H), 7.67 – 7.55 (m, 2H), 7.47 (dd, J = 8.9, 2.4 Hz, 1H), 7.35 – 7.28 (m, 2H), 7.05 (d, J = 9.2 Hz, 1H), 4.55 (dt, J = 13.6, 3.9 Hz, 2H), 3.39 – 3.21 (m, 3H), 2.28 (dt, J = 12.5, 3.7 Hz, 2H), 2.14 – 1.99 (m, 2H); 13 C NMR (101 MHz, CDCl 3 ) δ 181.71, 167.26, 157.13, 151.24, 146.33, 136.65, 130.17, 129.16, 128.16, 127.59, 125.92, 125.43, 123.56, 121.63, 121.07, 110.53, 44.64, 34.83, 29.02. [00162] In an embodiment, the method of synthesizing Compound 3 (5-(1-(8-methoxyquinolin-2- yl)piperidin-4-yl)-3-(4-(trifluoromethoxy)phenyl)-1,2,4-oxad iazole) is as follows: [00163] In an embodiment, preparation of compound 3 (5-(1-(8-Methoxyquinolin-2-yl)piperidin-4-yl)-3- (4-(trifluoromethoxy)phenyl)-1,2,4-oxadiazole) was performed. DIPEA (1.6 ml) was added to a suspension of 2-Chloro-8-methoxyquinoline (180 mg, 0.9 mmol) and intermediate 4 (300 mg, 0.9 mmol) in 1-BuOH (4.5 ml) and the mixture was allowed to stir at 130 ºC for 48 hours. The solvent was evaporated and the resulting residue was purified by column chromatography (silica gel, Petrol ether/EtOAc 5:1). Compound 3 was isolated as an orange solid (260 mg, 55%). [00164] HPLC-MS [M+H] + 471.17; MP: 124-125 ºC; 1 H NMR (400 MHz, DMSO-d 6 ) δ 8.18 – 8.09 (m, 2H), 8.02 (d, J = 9.2 Hz, 1H), 7.59 – 7.52 (m, 2H), 7.34 – 7.24 (m, 2H), 7.15 (t, J = 7.8 Hz, 1H), 7.04 (dd, J = 7.8, 1.4 Hz, 1H), 4.57 (dt, J = 13.6, 3.9 Hz, 2H), 3.91 (s, 3H), 3.50 (tt, J = 11.1, 3.9 Hz, 1H), 3.20 (ddd, J = 13.8, 11.5, 2.7 Hz, 2H), 2.22 (dd, J = 13.6, 3.6 Hz, 2H), 1.92 – 1.77 (m, 2H); 13 C NMR (101 MHz, DMSO-d 6 ) δ 182.89, 166.95, 156.50, 153.72, 150.81, 139.21, 137.93, 129.74, 125.88, 123.92, 122.40, 122.07, 121.69, 119.79, 110.70, 109.77, 56.12, 44.43, 34.34, 29.00. [00165] In an embodiment, the method of synthesizing Compound 4 (5-(1-(8-chloroquinolin-2- yl)piperidin-4-yl)-3-(4-(trifluoromethoxy)phenyl)-1,2,4-oxad iazole) is as follows: [00166] In an embodiment, preparation of compound 4 (5-(1-(8-chloroquinolin-2-yl)piperidin-4-yl)-3-(4- (trifluoromethoxy)phenyl)-1,2,4-oxadiazole) was performed. DIPEA (2 ml) was added to a suspension of 2,8-dichloroquinoline (146 mg, 0.74 mmol) and Intermediate 4 (300 mg, 0.74 mmol) in 1-BuOH (5 ml) and the mixture was allowed to stir at 130 ºC over a duration of 48 hours. The solvent was evaporated, and the resulting residue was purified by column chromatography (silica gel, Petrol ether/EtOAc 7:1) in order to obtain compound 4 as a colourless solid (260 mg, 73%). [00167] [M+H] + 475.13; MP: 109-110 ºC; 1 H NMR (400 MHz, DMSO-d 6 ) δ 8.25 – 8.07 (m, 3H), 7.83 – 7.70 (m, 2H), 7.67 – 7.56 (m, 2H), 7.46 (d, J = 9.2 Hz, 1H), 7.25 (t, J = 7.7 Hz, 1H), 4.70 (dt, J = 13.5, 3.9 Hz, 2H), 3.60 (tt, J = 11.0, 3.9 Hz, 1H), 3.38 – 3.25 (m, 2H), 2.42 – 2.23 (m, 2H), 1.99 – 1.64 (m, 2H); 13 C NMR (101 MHz, DMSO-d 6 ) δ 182.77, 166.94, 157.31, 150.80, 143.68, 138.46, 129.81, 129.73, 129.38, 127.12, 125.87, 124.23, 122.33, 122.07, 119.13, 111.40, 44.19, 34.25, 28.95. [00168] In an embodiment, the method of synthesizing Compound 5 (5-(1-(8-methoxyquinolin-2- yl)piperidin-4-yl)-3-(4-(trifluoromethyl)phenyl)-1,2,4-oxadi azole hydrochloride) is as follows:
[00169] In an embodiment, preparation of intermediate 5 (tert-Butyl 4-(3-(4-(trifluoromethyl)phenyl)- 1,2,4-oxadiazol-5-yl)piperidine-1-carboxylate) was performed. Carbonyldiimidazole (CDI) (779 mg, 4.8 mmol) was added to a solution of 1-(tert-butoxycarbonyl)piperidine-4-carboxylic acid (1g, 4.37 mmol) in PhMe (10 ml) and the mixture was allowed to stir at room temperature for 2 hours. 4- (trifluoromethyl)benzamidoxime (980 mg, 4.8 mmol) was added and the resulting mixture was allowed to stir at 110 ºC over a duration of 2.5 hours. The solvent was evaporated in high vacuum to give intermediate 5 as a clear oil (1.2 g). Intermediate 5 was taken crude to the next step. [00170] In an embodiment, preparation of intermediate 6 (5-(Piperidin-4-yl)-3-(4- (trifluoromethyl)phenyl)-1,2,4-oxadiazole trifluoroacetate) was performed. TFA (3 ml) was added to a solution of Intermediate 5 (1.2 g, 3 mmol) in DCM (5 ml). The mixture was allowed to stir at room temperature for 1 hour. The solvent was evaporated in high vacuum to give intermediate 6 a colourless solid (1.33 g). Intermediate 6 was taken crude to the next step. [00171] In an embodiment, preparation of compound 5 (5-(1-(8-Methoxyquinolin-2-yl)piperidin-4-yl)-3- (4-(trifluoromethyl)phenyl)-1,2,4-oxadiazole) was performed. DIPEA (5 ml) was added to a suspension of 2-chloro-8-methoxyquinoline (656 mg, 3.39 mmol) and Intermediate 6 (1.33 g, 3.39 mmol) in 1-BuOH (15 ml) and the mixture was allowed to stir at 130 ºC over a duration of 20 hours. The solvent was evaporated, and the resulting residue was purified by column chromatography (silica gel, Petrol ether/EtOAc 4:1). The product was dissolved in diethyl ether (5 mL) and a 2M solution of hydrochloric acid in diethyl ether (4 eq.) was added dropwise at 0 ºC. The precipitate was separated by filtration and was washed with cold diethylether. Compound 5 was isolated as an off-white solid (90 mg, 5%). [00172] HPLC-MS [M+H] + 455.17; MP: 110-113 ºC; 1 H NMR (500 MHz, DMSO-d 6 ) δ 8.22 (d, J = 8.1 Hz, 2H), 8.11 (d, J = 9.2 Hz, 1H), 7.93 (d, J = 8.1 Hz, 2H), 7.35 (dd, J = 17.1, 8.6 Hz, 2H), 7.22 (t, J = 7.8 Hz, 1H), 7.13 (d, J = 7.9 Hz, 1H), 4.52 (dt, J = 13.7, 4.0 Hz, 2H), 3.95 (s, 3H), 3.59 – 3.53 (m, 3H), 2.26 (dd, J = 13.7, 3.9 Hz, 2H), 1.98 – 1.87 (m, 2H). 13 C NMR (126 MHz, DMSO-d 6 ) δ 182.98, 128.36, 126.67, 119.97, 56.48, 44.98, 34.08, 28.95 [00173] In an embodiment, the method of synthesizing compound 6 (3-(3,5-dimethoxyphenyl)-5-(1-(8- methoxyquinolin-2-yl)piperidin-4-yl)-1,2,4-oxadiazole) is as follows: [00174] In an embodiment, preparation of intermediate 7 (tert-butyl 4-(3-(3,5-dimethoxyphenyl)-1,2,4- oxadiazol-5-yl)piperidine-1-carboxylate) was performed. Carbonyldiimidazole (CDI) (779 mg, 4.8 mmol) was added to a solution of 1-(tert-butoxycarbonyl)piperidine-4-carboxylic acid (1g, 4.37 mmol) in PhMe (10 ml) and the mixture was allowed to stir at room temperature for 2 hours. 3,5-Dimethoxy- benzamidoxime (980 mg, 4.8 mmol) was added and the resulting mixture was allowed to stir at 110 ºC over a duration of 2 hours. The solvent was evaporated in high vacuum and the product was purified by column chromatography (silica gel, Petrol ether/EtOAc 4:1). Intermediate 7 was isolated as a colourless solid (1.19 g, 70%). [00175] In an embodiment, preparation of intermediate 8 (3-(3,5-dimethoxyphenyl)-5-(piperidin-4-yl)- 1,2,4-oxadiazole trifluoroacetate) was performed. TFA (3 ml) was added to a solution of Intermediate 7 (1.19 g, 3.06 mmol) in DCM (5 ml). The mixture was allowed to stir at room temperature for 1 hour. The solvent was evaporated in high vacuum to give intermediate 8 (1 g, 70%) as a clear oil. Intermediate 8 was taken crude to the next step. [00176] In an embodiment, preparation of compound 6 (3-(3,5-dimethoxyphenyl)-5-(1-(8- methoxyquinolin-2-yl)piperidin-4-yl)-1,2,4-oxadiazole) was performed. DIPEA (5 ml) was added to a suspension of 2-chloro-8-methoxyquinoline (400 mg, 2.06 mmol) and Intermediate 8 (1.00 g, 2.48 mmol) in 1-BuOH (15 ml) and the mixture was allowed to stir at 130 ºC over a duration of 20 hours. The solvent was evaporated, and the resulting residue was purified by column chromatography (silica gel, Petrol ether/EtOAc 4:1) in order to obtain compound 6 as an off-white solid (1.05 g, 95%). [00177] HPLC-MS [M+H] + 447.19; MP: 124-127 ºC; 1 H NMR (400 MHz, CDCl 3 ) δ 7.93 (d, J = 9.2 Hz, 1H), 7.31 – 7.14 (m, 4H), 7.08 (d, J = 9.2 Hz, 1H), 6.99 (dd, J = 7.6, 1.4 Hz, 1H), 6.62 (t, J = 2.4 Hz, 1H), 4.61 (dt, J = 13.1, 3.5 Hz, 2H), 4.06 (s, 3H), 3.88 (s, 6H), 3.38 – 3.22 (m, 3H), 2.32 dd, J = 13.5, 3.8 Hz, 2H), 2.15 – 2.07 (m 2H). 13 C NMR (101 MHz, CDCl 3 ) δ 181.50, 168.24, 161.05, 156.74, 153.53, 139.18, 137.72, 128.52, 123.97, 122.33, 119.45, 110.05, 108.78, 105.10, 104.01, 56.15, 55.59, 44.78, 34.91, 29.24. [00178] In an embodiment, the method of synthesizing compound 7 (5-(1-(8-methoxyquinolin-2- yl)piperidin-4-yl)-3-(3-(trifluoromethyl)phenyl)-1,2,4-oxadi azole) is as follows: [00179] In an embodiment, preparation of intermediate 9 (tert-butyl 4-(3-(3-(trifluoromethyl)phenyl)- 1,2,4-oxadiazol-5-yl)piperidine-1-carboxylate) was performed. Carbonyldiimidazole (CDI) (779 mg, 4.8 mmol) was added to a solution of 1-(tert-butoxycarbonyl)piperidine-4-carboxylic acid (1g, 4.37 mmol) in PhMe (10 ml) and the mixture was allowed to stir at room temperature for 2 hours. 3- (Trifluoromethyl)benzamidoxime (980 mg, 4.8 mmol) was added and the resulting mixture was allowed to stir at 110 ºC over a duration of 2 hours. The solvent was evaporated in high vacuum and the product was purified by column chromatography (silica gel, Petrol ether/EtOAc 4:1). Intermediate 9 was isolated as an oil (1.15 g, 66%). [00180] In an embodiment, preparation of intermediate 10 (5-(piperidin-4-yl)-3-(3- (trifluoromethyl)phenyl)-1,2,4-oxadiazole trifluoroacetate) was performed. TFA (3 ml) was added to a solution of Intermediate 9 (1.15 g, 2.9 mmol) in DCM (5 ml). The mixture was allowed to stir at room temperature for 1 hour. The solvent was evaporated in high vacuum to give intermediate 10 (1 g, 84%) as a clear oil. Intermediate 10 was taken crude to the next step. [00181] In an embodiment, preparation of compound 7 (5-(1-(8-methoxyquinolin-2-yl)piperidin-4-yl)-3- (3-(trifluoromethyl)phenyl)-1,2,4-oxadiazole) was performed. DIPEA (5 ml) was added to a suspension of 2-chloro-8-methoxyquinoline (393 mg, 2.03 mmol) and Intermediate 10 (1.00 g, 2.43 mmol) in 1-BuOH (15 ml) and the mixture was allowed to stir at 130 ºC over a duration of 20 hours. The solvent was evaporated, and the resulting residue was purified by column chromatography (silica gel, Petrol ether/EtOAc 4:1) in order to obtain compound 7 as an off-white solid (968 mg, 88%). [00182] HPLC-MS [M+H] + 455.17; MP: 100-105 ºC; 1 H NMR (400 MHz, CDCl 3 ) δ 8.38 (bs, 1H), 8.29 (d, J = 7.8 Hz, 1H), 7.94 (d, J = 9.1 Hz, 1H), 7.78 (d, J = 7.8 Hz, 1H), 7.63 (t, J = 7.8 Hz, 1H), 7.27 – 7.15 (m, 2H), 7.09 (d, J = 9.1 Hz, 1H), 7.00 (dd, J = 7.5, 1.4 Hz, 1H), 4.61 (dt, J = 13.7, 4.0 Hz, 2H), 4.05 (s, 3H), 3.31 (m, 3H), 2.34 (dt, J = 13.7, 3.6 Hz, 2H), 2.20 – 2.05 (m, 2H); 13 C NMR (101 MHz, CDCl 3 ) δ 182.04, 171.57, 167.28, 156.63, 153.43, 137.89, 133.25, 130.55, 129.42, 127.78, 127.70, 124.44, 123.96, 122.48, 119.45, 111.98, 110.10, 108.89, 56.15, 44.84, 34.86, 29.20. [00183] In an embodiment, the method of synthesizing compound 8 (3-(3,5-bis(trifluoromethyl)phenyl)- 5-(1-(8-methoxyquinolin-2-yl)piperidin-4-yl)-1,2,4-oxadiazol e) is as follows: [00184] In an embodiment, preparation of intermediate 11 (tert-butyl 4-(3-(3,5- bis(trifluoromethyl)phenyl)-1,2,4-oxadiazol-5-yl)piperidine- 1-carboxylate) was performed. Carbonyldiimidazole (CDI) (779 mg, 4.8 mmol) was added to a solution of 1-(tert- butoxycarbonyl)piperidine-4-carboxylic acid (1g, 4.37 mmol) in PhMe (10 ml) and the mixture was allowed to stir at room temperature for 2 hours. 3,5-Bis(trifluoromethyl)benzamidoxime (1.3 g, 4.8 mmol) was added and the resulting mixture was allowed to stir at 110 ºC over a duration of 2 hours. The solvent was evaporated in high vacuum and the product was purified by column chromatography (silica gel, Petrol ether/EtOAc 4:1). Intermediate 11 was isolated as a clear oil (1.18 g, 59%). [00185] In an embodiment, preparation of intermediate 12 (3-(3,5-bis(trifluoromethyl)phenyl)-5- (piperidin-4-yl)-1,2,4-oxadiazole trifluoroacetate) was performed. TFA (3 ml) was added to a solution of Intermediate 11 (1.18 g, 2.54 mmol) in DCM (5 ml). The mixture was allowed to stir at room temperature for 1 hour. The solvent was evaporated in high vacuum to give intermediate 12 (1 g, 70%) as a clear oil. Intermediate 12 was taken crude to the next step. [00186] In an embodiment, preparation of compound 8 (3-(3,5-bis(trifluoromethyl)phenyl)-5-(1-(8- methoxyquinolin-2-yl)piperidin-4-yl)-1,2,4-oxadiazole) was performed. DIPEA (5 ml) was added to a suspension of 2-chloro-8-methoxyquinoline (440 mg, 2.28 mmol) and Intermediate 12 (1.00 g, 2.74 mmol) in 1-BuOH (15 ml) and the mixture was allowed to stir at 130 ºC over a duration of 20 hours. The solvent was evaporated, and the resulting residue was purified by column chromatography (silica gel, Petrol ether/EtOAc 4:1) in order to obtain compound 8 as an off-white solid (397 mg, 50%). [00187] HPLC-MS [M+H] + 523.13; MP: 121-125 ºC; 1 H NMR (400 MHz, CDCl 3 ) δ 8.58 (bs, 2H), 8.04 (d, J = 7.6 Hz, 1H), 7.94 (d, J = 9.2 Hz, 1H), 7.30 – 7.16 (m, 2H), 7.09 (d, J = 9.2 Hz, 1H), 7.00 (dd, J = 7.5, 1.5 Hz, 1H), 4.62 (dt, J = 13.6, 3.9 Hz, 2H), 4.06 (s, 3H), 3.43 – 3.25 (m, 3H), 2.34 (dt, J = 12.9, 4.0 Hz, 2H), 2.21 – 2.06 (m, 2H); 13 C NMR (101 MHz, CDCl 3 ) δ 182.68, 166.29, 156.70, 153.55, 137.78, 132.66, 132.32, 129.13, 124.58, 124.29, 124.02, 122.44, 119.46, 116.73, 110.04, 108.80, 56.14, 44.75, 34.93, 29.17. [00188] In an embodiment, the method of synthesizing compound 9 (5-(1-(8-methoxyquinolin-2- yl)piperidin-4-yl)-3-(pyridin-4-yl)-1,2,4-oxadiazole) is as follows: [00189] In an embodiment, preparation of compound 9 (5-(1-(8-methoxyquinolin-2-yl)piperidin-4-yl)-3- (pyridin-4-yl)-1,2,4-oxadiazole) was performed. DIPEA (5 ml) was added to a suspension of 2-chloro-8- methoxyquinoline (380 mg, 1.97 mmol) and 4-[5-(piperidin-4-yl)-1,2,4-oxadiazol-3-yl]pyridine (500 mg, 2.17 mmol) in 1-BuOH (15 ml) and the mixture was allowed to stir at 130 ºC over a duration of 20 hours. The solvent was evaporated, and the resulting residue was purified by column chromatography (silica gel, DCM/MeOH 10%) in order to obtain compound 9 as a brown solid (250 mg, 34%). [00190] HPLC-MS [M+H] + 388.21; MP: not aplicable (oil); 1 H NMR (400 MHz, MeOD-d 4 ) δ 9.09 (bs, 2H), 8.74 – 8.69 (m, 2H), 8.45 (d, J = 9.4 Hz, 1H), 7.66 (d, J = 9.2 Hz, 1H), 7.55 – 7.43 (m, 3H), 4.50 – 4.45 (m, 2H), 4.14 (s, 3H), 3.83 – 3.75 (m, 3H), 2.55 – 2.50 (m, 2H), 2.27 – 2.21 (m, 2H). 13 C NMR (101 MHz, MeOD- d 4 ) δ 143.75, 142.96, 126.07, 124.70, 119.59, 112.64, 55.83, 46.38, 32.97, 28.22. [00191] In an embodiment, the method of synthesizing compound 10 (5-(1-(8-methoxyquinolin-2- yl)piperidin-4-yl)-3-(pyridin-3-yl)-1,2,4-oxadiazole hydrochloride) is as follows: [00192] In an embodiment, preparation of intermediate 13 (tert-butyl 4-(3-(pyridin-3-yl)-1,2,4-oxadiazol- 5-yl)piperidine-1-carboxylate) was performed. Carbonyldiimidazole (CDI) (779 mg, 4.8 mmol) was added to a solution of 1-(tert-butoxycarbonyl)piperidine-4-carboxylic acid (1g, 4.37 mmol) in PhMe (10 ml) and the mixture was allowed to stir at room temperature for 2 hours. (Z)-N'-hydroxynicotinimidamide (660 mg, 4.8 mmol) was added and the resulting mixture was allowed to stir at 110 ºC over a duration of 2 hours. The solvent was evaporated in high vacuum and the product was purified by column chromatography (silica gel, EtOAc). Intermediate 13 was isolated as a clear oil (788 mg, 58%). [00193] In an embodiment, preparation of intermediate 14 (5-(piperidin-4-yl)-3-(pyridin-3-yl)-1,2,4- oxadiazole trifluoroacetate) was performed. TFA (3 ml) was added to a solution of Intermediate 13 (787 mg, 2.39 mmol) in DCM (5 ml). The mixture was allowed to stir at room temperature for 1 hour. The solvent was evaporated in high vacuum to give intermediate 14 (1.78 g) as a clear oil. Intermediate 14 was taken crude to the next step. [00194] In an embodiment, preparation of compound 10 (5-(1-(8-methoxyquinolin-2-yl)piperidin-4-yl)-3- (pyridin-3-yl)-1,2,4-oxadiazole hydrochloride) was performed. DIPEA (5 ml) was added to a suspension of 2-chloro-8-methoxyquinoline (500 mg, 2.58 mmol) and Intermediate 14 (900 mg, 2.84 mmol) in 1-BuOH (15 ml) and the mixture was allowed to stir at 130 ºC over a duration of 20 hours. The solvent was evaporated, and the resulting residue was purified by column chromatography (silica gel, Petrol ether/EtOAc 3:1). The product was dissolved in EtOAc (5 mL) and a 2M solution of hydrochloric acid in diethyl ether (4 eq.) was added dropwise a 0 ºC. The precipitate was separated by filtration and was washed with cold EtOAc. Compound 10 was isolated as a brown solid (128 mg, 13%). [00195] HPLC-MS [M+H] + 388.22; MP: not aplicable (oil); 1 H NMR (400 MHz, MeOD-d 4 ) δ 9.54 (bs, 1H), 9.28 (dt, J = 8.3, 1.7 Hz, 1H), 9.13 – 9.06 (m, 1H), 8.48 (d, J = 9.8 Hz, 1H), 8.34 (ddd, J = 8.3, 5.8, 0.8 Hz, 1H), 7.67 (d, J = 9.7 Hz, 1H), 7.60 – 7.50 (m, 2H), 7.52 – 7.42 (m, 1H), 4.50 (dt, J = 14.2, 4.0 Hz, 2H), 4.17 (s, 3H), 3.85 – 3.74 (m 3H), 2.59 – 2.48 (m, 2H), 2.34 – 2.17 (m, 2H); 13 C NMR (101 MHz, MeOD-d 4 ) δ 182.70, 163.93, 151.63, 144.22, 143.73, 143.53, 140.37, 127.97, 127.30, 126.39, 126.05, 121.87, 119.58, 112.63, 112.55, 55.84, 32.92, 28.26. [00196] In an embodiment, the method of synthesizing compound 11 (5-(1-(8-methoxyquinolin-2- yl)piperidin-4-yl)-3-(6-(trifluoromethyl)pyridin-3-yl)-1,2,4 -oxadiazole) is as follows: [00197] In an embodiment, preparation of intermediate 15 (tert-butyl 4-(3-(6-(trifluoromethyl)pyridin-3- yl)-1,2,4-oxadiazol-5-yl)piperidine-1-carboxylate) was performed. Carbonyldiimidazole (CDI) (779 mg, 4.8 mmol) was added to a solution of 1-(tert-butoxycarbonyl)piperidine-4-carboxylic acid (1g, 4.37 mmol) in PhMe (10 ml) and the mixture was allowed to stir at room temperature for 2 hours. 6- (Trifluoromethyl)nicotinamidoxime (1 g, 4.8 mmol) was added and the resulting mixture was allowed to stir at 110 ºC over a duration of 2 hours. The solvent was evaporated in high vacuum and the product was purified by column chromatography (silica gel, Petrol ether/EtOAc 4:1). Intermediate 15 was isolated as a clear oil (1.1 g, 68%). [00198] In an embodiment, preparation of intermediate 16 (5-(piperidin-4-yl)-3-(6- (trifluoromethyl)pyridin-3-yl)-1,2,4-oxadiazole trifluoroacetate) was performed. TFA (3 ml) was added to a solution of Intermediate 15 (1.1 g, 2.77 mmol) in DCM (5 ml). The mixture was allowed to stir at room temperature for 1 hour. The solvent was evaporated in high vacuum to give intermediate 16 (1.09 g, 100%) as a clear oil. Intermediate 16 was taken crude to the next step. [00199] In an embodiment, preparation of compound 11 (5-(1-(8-methoxyquinolin-2-yl)piperidin-4-yl)-3- (6-(trifluoromethyl)pyridin-3-yl)-1,2,4-oxadiazole was performed. DIPEA (10 ml) was added to a suspension of 2-chloro-8-methoxyquinoline (700 mg, 3.18 mmol) and Intermediate 16 (1.09 g, 2.65 mmol) in 1-BuOH (20 ml) and the mixture was allowed to stir at 130 ºC over a duration of 20 hours. The solvent was evaporated, and the resulting residue was purified by column chromatography (silica gel, Petrol ether/EtOAc 4:1) in order to obtain compound 11 as a yellow solid (288 mg, 24%). [00200] HPLC-MS [M+H] + 456.17; MP: 106-109 ºC; 1 H NMR (400 MHz, CDCl 3 ) δ 9.43 (bs, 1H), 8.56 (dd, J = 8.3, 2.0 Hz, 1H), 7.94 (d, J = 9.1 Hz, 1H), 7.83 (dd, J = 8.3, 0.8 Hz, 1H), 7.27 – 7.18 (m, 2H), 7.08 (d, J = 9.2 Hz, 1H), 7.00 (dd, J = 7.5, 1.5 Hz, 1H), 4.61 (dt, J = 13.6, 3.9 Hz, 2H), 4.05 (s, 3H), 3.42 – 3.25 (m, 3H), 2.34 (dt, J = 12.1, 3.6 Hz, 2H), 2.19 – 2.03 (m, 2H); 13 C NMR (101 MHz, CDCl 3 ) δ 182.58, 165.41, 156.54, 153.38, 150.18, 149.83, 148.75, 138.76, 138.00, 136.18, 125.87, 123.96, 122.58, 120.54, 119.45, 110.09, 108.94, 56.14, 44.85, 34.85, 29.17. [00201] In an embodiment, the method of synthesizing compound 12 (3-(3-methoxyphenyl)-5-(1-(8- methoxyquinolin-2-yl)piperidin-4-yl)-1,2,4-oxadiazole hydrochloride) is as follows:
[00202] In an embodiment, preparation of Intermediate 17 (Ethyl 1-(8-Methoxyquinolin-2-yl)piperidine- 4-carboxylate) was performed. DIPEA (10 ml) was added to a suspension of 2-Chloro-8-methoxyquinoline (2 g, 10.3 mmol) and ethyl isonicotinate (1.78 g, 11.36 mmol) in 1-BuOH (20 ml) and the mixture was allowed to stir at 130 ºC for 20 hours. The solvent was evaporated and the resulting residue was purified by column chromatography (silica gel, Petrol ether/EtOAc 4:1) and Intermediate 17 was isolated as a clear oil (1.62 g, 51%). [00203] In an embodiment, preparation of intermediate 18 (1-(8-Methoxyquinolin-2-yl)piperidine-4- carboxylic acid) was performed. A 5N aqueous solution of potassium hydroxide (10 ml) was added to a solution of Intermediate 17 (1.62 g, 5.16 mmol) in 1,4-dioxane (10 ml). The solution was allowed to stir at 60 ºC over a duration of 5 hours. When the reaction was complete, water was added and the pH was reduced to pH2 with acetic acid. The product was extracted with EtOAc, the organic layer was separated, dried with anhydrous sodium sulphate, was filtered and evaporated in high vacuum to give Intermediate 18 as a clear oil (1.17 g, 80%). [00204] In an embodiment, preparation of compound 12 (3-(3-methoxyphenyl)-5-(1-(8-methoxyquinolin- 2-yl)piperidin-4-yl)-1,2,4-oxadiazole hydrochloride) was performed. CDI (273 mg, 1.68 mmol) was added to a solution of Intermediate 18 (438 mg, 1.53 mmol) in PhMe (5 mL) and the reaction mixture was allowed to stir at room temperature for 2 hours. Then 3-methoxy-benzamidoxime (279 mg, 1.68 mmol) was added and the reaction mixture and it was allowed to stir for 1 hour at room temperature and for 2 hours at 110 ºC. The solvent was evaporated in high vacuum and the resulting residue was purified by column chromatography (silica gel, Petrol ether/EtOAc 4:1). The product was dissolved in EtOAc (5 mL) and a 2M solution of hydrochloric acid in diethyl ether (1 mL) was added dropwise a 0 ºC. The precipitate was separated by filtration and was washed with cold diethyl ether. Compound 12 was isolated as a colourless solid (181 mg, 26%). [00205] HPLC-MS [M+H] + 417.24; MP: 77-78 ºC; 1 H NMR (500 MHz, MeOD-d 4 ) δ 8.43 (d, J = 9.7 Hz, 1H), 7.66 – 7.55 (m, 3H), 7.55 – 7.47 (m, 2H), 7.50 – 7.39 (m, 2H), 7.11 (ddd, J = 8.4, 2.7, 1.0 Hz, 1H), 4.44 (dt, J = 14.4, 4.1 Hz, 2H), 4.13 (s, 3H), 3.86 (s, 3H), 3.75 (ddd, J = 14.0, 11.1, 3.1 Hz, 2H), 3.64 (tt, J = 10.5, 4.2 Hz, 1H), 2.46 (dt, J = 12.8, 4.0 Hz, 2H), 2.26 – 2.17 (m, 2H); 13 C NMR (126 MHz, MeOD-d 4 ) δ 180.98, 168.06, 164.10, 160.11, 151.76, 147.62, 143.52, 129.88, 127.69, 125.93, 121.91, 119.58, 119.22, 116.84, 112.51, 112.41, 112.09, 55.82, 54.52, 46.36, 32.88, 28.37. [00206] In an embodiment, the method of synthesizing compound 13 (5-(1-(8-methoxyquinolin-2- yl)piperidin-4-yl)-3-(3-(trifluoromethoxy)phenyl)-1,2,4-oxad iazole) is as follows: [00207] In an embodiment, preparation of compound 13 (5-(1-(8-methoxyquinolin-2-yl)piperidin-4-yl)-3- (3-(trifluoromethoxy)phenyl)-1,2,4-oxadiazole) was performed. CDI (311 mg, 2.63 mmol) was added to a solution of Intermediate 18 (500 mg, 1.75 mmol) in PhMe (10 mL) and the reaction mixture was allowed to stir at room temperature for 2 hours. Then N'-Hydroxy-3-(trifluoromethoxy)benzimidamide (423 mg, 2.63 mmol) was added and the reaction mixture was allowed to stir for 1 hour at room temperature and for 2 hours at 110 ºC. The solvent was evaporated in high vacuum and the resulting residue was purified by column chromatography (silica gel, Petrol ether/EtOAc 4:1) in order to obtain compound 13 as an off- white solid (234 mg, 28%). [00208] HPLC-MS [M+H] + 471.17; MP: 140-143 ºC; 1 H NMR (400 MHz, MeOD-d 4 ) δ 8.45 (d, J = 9.7 Hz, 1H), 8.08 (dt, J = 7.8, 1.2 Hz, 1H), 7.94 (bs, 1H), 7.69 – 7.59 (m, 2H), 7.56 – 7.39 (m, 4H), 4.45 (dt, J = 14.2, 4.2 Hz, 2H), 4.14 (s, 3H), 3.78 (ddd, J = 14.0, 11.0, 3.1 Hz, 2H), 3.67 (tt, J = 10.4, 4.3 Hz, 1H), 2.54 – 2.44 (m, 2H), 2.30 – 2.15 (m, 2H); 13 C NMR (101 MHz, MeOD-d 4 ) δ 181.42, 174.23, 167.02, 151.61, 149.47, 147.44, 143.67, 130.76, 128.81, 126.39, 126.02, 125.60, 123.52, 121.86, 119.57, 119.30, 112.60, 112.52, 55.82, 46.39, 32.81, 28.31. [00209] In an embodiment, the method of synthesizing compound 14 (3-(4-methoxyphenyl)-5-(1-(8- methoxyquinolin-2-yl)piperidin-4-yl)-1,2,4-oxadiazole) is as follows: [00210] In an embodiment, preparation of compound 14 (3-(4-methoxyphenyl)-5-(1-(8-methoxyquinolin- 2-yl)piperidin-4-yl)-1,2,4-oxadiazole) was performed. CDI (311 mg, 2.53 mmol) was added to a solution of Intermediate 18 (500 mg, 1.75 mmol) in PhMe (10 mL) and the reaction mixture was allowed to stir at room temperature for 2 hours. Then N'-Hydroxy-4-methoxybenzimidamide (329 mg, 2.53 mmol) was added and the reaction mixture was allowed to stir for 1 hour at room temperature and 2 hours at 110 ºC. The solvent was evaporated in high vacuum and the resulting residue was purified by column chromatography (silica gel, Petrol ether/EtOAc 4:1) in order to obtain compound 14 as an off-white solid (378 mg, 52%). [00211] HPLC-MS [M+H] + 417.25; MP: 90-100 ºC; 1 H NMR (500 MHz, CDCl 3 ) δ 8.06 – 7.99 (m, 2H), 7.92 (d, J = 9.2 Hz, 1H), 7.24 (dd, J = 8.1, 1.4 Hz, 1H), 7.19 (t, J = 7.8 Hz, 1H), 7.07 (d, J = 9.1 Hz, 1H), 7.02 – 6.95 (m, 3H), 4.58 (dt, J = 13.6, 4.1 Hz, 2H), 4.05 (s, 3H), 3.87 (s, 3H), 3.36 – 3.22 (m, 3H), 2.31 (dt, J = 12.1, 3.7 Hz, 2H), 2.16 – 2.03 (m, 2H); 13 C NMR (126 MHz, CDCl 3 ) δ 181.14, 167.97, 161.88, 156.52, 138.05, 129.04, 123.87, 122.56, 119.44, 119.33, 114.23, 110.19, 109.02, 60.40, 56.19, 55.38, 45.02, 34.76, 29.24, 14.21. [00212] In an embodiment, the method of synthesizing compound 15 (5-(1-(6-chloroquinolin-2- yl)piperidin-4-yl)-3-(pyridin-3-yl)-1,2,4-oxadiazole hydrochloride) is as follows:
[00213] In an embodiment, preparation of Intermediate 19 (ethyl 1-(6-chloroquinolin-2-yl)piperidine-4- carboxylate) was performed. DIPEA (5 ml) was added to a suspension of 2,6-dichloroquinoline (1 g, 5.1 mmol) and ethyl isonicotinate (873 mg, 5.6 mmol) in 1-BuOH (20 ml) and the mixture was allowed to stir at 130 ºC for a duration of 20 hours. The solvent was evaporated and the resulting residue was purified by column chromatography (silica gel, Petrol ether/EtOAc 4:1) and Intermediate 19 was isolated as a clear oil (1.1 g, 68%). [00214] In an embodiment, preparation of intermediate 20 (1-(6-chloroquinolin-2-yl)piperidine-4- carboxylic acid) was performed. A 5N aqueous solution of potassium hydroxide (20 ml) was added to a solution of Intermediate 19 (1.1 g, 3.46 mmol) in 1,4-dioxane (20 ml). The solution was allowed to stir at 80 ºC over a duration of 2 hours. Some of the solvent was evaporated in vacuum and the precipitated starting material was removed by filtration. Water was added and the mixture was acidified to pH 1 with hydrochloric acid at 0 °ºC. The precipitate was separated by filtration and was washed with water. The intermediate 20 was isolated as a colourless solid (700 mg, 70%). [00215] In an embodiment, preparation of compound 15 (5-(1-(6-chloroquinolin-2-yl)piperidin-4-yl)-3- (pyridin-3-yl)-1,2,4-oxadiazole hydrochloride) was performed. CDI (326 mg, 2.01 mmol) was added to a solution of Intermediate 20 (390 mg, 1.34 mmol) in PhMe (10 mL) and the reaction mixture was allowed to stir at room temperature for 2 hours. Then 3-pyridylamidoxime (276 mg, 2.01 mmol) was added and the reaction mixture was allowed to stir for 1 hour at room temperature and for 20 hours at 110 ºC. The solvent was evaporated in high vacuum and the resulting residue was purified by column chromatography (silica gel, Petrol ether/EtOAc 4:1). The product was dissolved in EtOAc (5 mL) and a 2M solution of hydrochloric acid in diethyl ether (1 mL) was added dropwise a 0 ººC. The precipitate was separated by filtration and was washed with cold diethyl ether. Compound 15 was isolated as pale yellow solid (420 mg, 80%). [00216] HPLC-MS [M+H] + 392.19; MP: 271-274 ºC; 1 H NMR (400 MHz, DMSO-d 6 ) δ 9.23 (bs, 1H), 8.88 (dd, J = 5.1, 1.6 Hz, 1H), 8.56 (m, 2H), 8.40 (d, J = 9.8 Hz, 1H), 8.07 (d, J = 2.4 Hz, 1H), 7.88 – 7.76 (m, 2H), 7.74 (d, J = 9.8 Hz, 1H), 4.77 – 4.68 (m, 2H), 3.80 – 3.66 (m, 3H), 2.34 (dt, J = 11.9, 3.7 Hz, 2H), 2.15 – 2.00 (m, 2H); 13 C NMR (101 MHz, DMSO-d 6 ) δ 182.47, 165.71, 151.92, 150.51, 146.07, 141.83, 137.56, 136.48, 132.58, 129.47, 127.54, 125.88, 123.83, 122.42, 120.82, 114.54, 47.17, 33.09, 28.94. [00217] In an embodiment, the method of synthesizing compound 16 (5-(1-(8-methoxyquinolin-2- yl)piperidin-4-yl)-3-(pyrazin-2-yl)-1,2,4-oxadiazole hydrochloride) is as follows: [00218] In an embodiment, the method of synthesizing compound 16 (5-(1-(8-methoxyquinolin-2- yl)piperidin-4-yl)-3-(pyrazin-2-yl)-1,2,4-oxadiazole hydrochloride) was performed. CDI (426 mg, 2.63 mmol) was added to a solution of Intermediate 18 (500 mg, 1.75 mmol) in PhMe (10 mL) and the reaction mixture was allowed to stir at room temperature for 2 hours. Then N'-hydroxypyrazine-2- carboximidamide (363 mg, 2.63 mmol) was added and the reaction mixture was allowed to stir for 1 hour at room temperature and for 17 hours at 110 ºC. The solvent was evaporated in high vacuum and the resulting residue was purified by column chromatography (silica gel, Petrol ether/EtOAc 4:1). The product was dissolved in EtOAc (5 mL) and a 2M solution of hydrochloric acid in diethyl ether (1 mL) was added dropwise a 0 ºC. The precipitate was separated by filtration and was washed with cold diethyl ether. Compound 16 was isolated as pale yellow solid (212 mg, 29%). [00219] HPLC-MS [M+H] + 389.22; MP: 125-129 ºC; 1 H NMR (400 MHz, DMSO-d 6 ) δ 9.26 (bs, 1H), 8.91 – 8.84 (m, 2H), 8.41 (d, J = 9.6 Hz, 1H), 7.66 (d, J = 9.7 Hz, 1H), 7.50 (dd, J = 7.7, 1.5 Hz, 1H), 7.48 – 7.35 (m, 2H), 4.45 (dt, J = 13.8, 3.9 Hz, 2H), 4.07 – 4.02 (m, 5H), 3.76 – 3.62 (m, 1H), 2.34 (dd, J = 13.9, 3.8 Hz, 2H), 2.12 – 1.97 (m, 2H); 13 C NMR (101 MHz, DMSO-d 6 ) δ 182.72, 166.41, 147.58, 145.72, 144.22, 142.08, 122.48, 120.21, 56.88, 46.69, 33.16, 28.86. [00220] In an embodiment, the method of synthesizing compound 17 (7-hydroxy-8-methoxy-2-(4-(3- (pyridin-3-yl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl)quinoline 1-oxide) is as follows: [00221] In an embodiment, preparation of compound 17 (7-hydroxy-8-methoxy-2-(4-(3-(pyridin-3-yl)- 1,2,4-oxadiazol-5-yl)piperidin-1-yl)quinoline 1-oxide) was performed. Urea hydrogen peroxide (304 mg, 3.23 mmol) was added to a solution of Compound 10 (270 mg, 0.70 mmol) in DCM (10 mL). The reaction mixture was cooled down to 0 ºC and trifluoroacetic anhydride (0.4 mL, 2.6 mmol) was added dropwise. The mixture was allowed to stir at room temperature until completion. Fresh hydrogen peroxide and trifluoroacetic anhydride were added once a day for 6 days. The reaction mixture was diluted with DCM and was quenched with a saturated aqueous solution of sodium thiosulfate. The organic layer was separated, re-washed with a saturated solution of sodium thiosulfate, water followed by brine. The organic layer was dried over anhydrous sodium sulphate and evaporated under reduced pressure. Compound 17 was isolated as a brown solid (108 mg, 37%). [00222] HPLC-MS [M+H] + 422.16; MP: 75-80 ºC; 1 H NMR (500 MHz, DMSO-d 6 ) δ 9.16 (bs, 1H), 8.81 – 8.75 (m, 1H), 8.37 (dt, J = 8.0, 2.0 Hz, 1H), 8.18 (d, J = 9.4 Hz, 1H), 7.62 (dd, J = 8.0, 4.9 Hz, 1H), 7.44 (d, J = 9.4 Hz, 1H), 7.26 (d, J = 8.3 Hz, 1H), 7.03 (d, J = 8.4 Hz, 1H), 4.57 (dt, J = 13.7, 4.2 Hz, 2H), 3.90 (s, 3H), 3.34 – 3.21 m, 3H), 2.23 (dt, J = 12.7, 3.9 Hz, 2H), 1.92 – 1.78 (m, 2H); 13 C NMR (126 MHz, DMSO-d 6 ) δ 182.91, 166.14, 156.43, 152.80, 152.44, 147.87, 135.44, 134.40, 124.94, 123.12, 122.18, 121.40, 120.64, 111.82, 110.00, 56.39, 44.38, 34.20, 28.98. [00223] In an embodiment, the method of synthesizing compound 18 (5-(1-(8-chloroquinolin-2- yl)piperidin-4-yl)-3-(pyridin-3-yl)-1,2,4-oxadiazole hydrochloride) is as follows:
[00224] In an embodiment, preparation of Intermediate 21 (ethyl 1-(8-chloroquinolin-2-yl)piperidine-4- carboxylate) was performed. DIPEA (10 ml) was added to a suspension of 2,8-dichloroquinoline (2 g, 10 mmol) and ethyl isonicotinate (1.7 g, 11 mmol) in 1-BuOH (40 ml) and the mixture was allowed to stir at 130 ºC for a duration of 20 hours. The solvent was evaporated and the resulting residue was purified by column chromatography (silica gel, Petrol ether/EtOAc 4:1) and Intermediate 21 was isolated as a clear oil (1.8 g, 57%). [00225] In an embodiment, preparation of intermediate 22 (1-(8-chloroquinolin-2-yl)piperidine-4- carboxylic acid) was performed. A 5N aqueous solution of potassium hydroxide (20 ml) was added to a solution of Intermediate 21 (1.8 g, 5.65 mmol) in 1,4-dioxane (20 ml). The solution was allowed to stir at 80 ºC over a duration of 3 hours. The solvent was evaporated in vacuum and the mixture was acidified to pH 1 with hydrochloric acid at 0 ºC. The precipitate was separated by filtration and was washed with water. The intermediate 22 was isolated as a yellow solid (1.9 g). [00226] In an embodiment, preparation of compound 18 (5-(1-(8-chloroquinolin-2-yl)piperidin-4-yl)-3- (pyridin-3-yl)-1,2,4-oxadiazole hydrochloride) was performed. CDI (470 mg, 2.90 mmol) was added to a solution of Intermediate 22 (560 mg, 1.93 mmol) in PhMe (10 mL) and the reaction mixture was allowed to stir at room temperature for 2 hours. Then N'-Hydroxynicotinimidamide (397 mg, 2.90 mmol) was added and the reaction mixture was allowed to stir for 1 hour at room temperature and 23 hours at 110 ºC. The solvent was evaporated in high vacuum and the resulting residue was purified by column chromatography (silica gel, Petrol ether/EtOAc 1:1). The product was dissolved in EtOAc (5 mL) and a 2M solution of hydrochloric acid in diethyl ether (1 mL) was added dropwise a 0 ºC. The precipitate was separated by filtration and was washed with cold diethyl ether. Compound 18 was isolated as pale yellow solid (504 mg, 62%). [00227] HPLC-MS [M+H] + 392.22; MP: 223-228 ºC; 1 H NMR (400 MHz, DMSO-d 6 ) δ 9.24 (bs, 1H), 8.91 – 8.84 (m, 1H), 8.57 (dt, J = 8.0, 1.9 Hz, 1H), 8.13 (d, J = 9.2 Hz, 1H), 7.79 (dd, J = 8.0, 5.0 Hz, 1H), 7.75 – 7.67 (m, 2H), 7.41 (d, J = 9.2 Hz, 1H), 7.20 (t, J = 7.7 Hz, 1H), 4.65 (dt, J = 13.6, 3.8 Hz, 2H), 3.59 (tt, J = 11.0, 4.0 Hz, 1H), 3.32 (ddd, J = 13.8, 11.4, 2.7 Hz, 2H), 2.25 (dd, J = 13.5, 3.7 Hz, 2H), 1.96 – 1.81 (m, 2H); 13 C NMR (101 MHz, DMSO-d 6 ) δ 183.12, 165.67, 157.23, 150.41, 146.06, 143.50, 138.56, 137.65, 129.88, 129.24, 127.15, 125.85, 124.22, 123.92, 122.41, 111.46, 44.23, 34.23, 28.92. [00228] In an embodiment, the method of synthesizing compound 19 (5-(1-(8-chloroquinolin-2- yl)piperidin-4-yl)-3-(4-fluorophenyl)-1,2,4-oxadiazole) is as follows: [00229] In an embodiment, preparation of compound 19 (5-(1-(8-chloroquinolin-2-yl)piperidin-4-yl)-3-(4- fluorophenyl)-1,2,4-oxadiazole) was performed. CDI (470 mg, 2.90 mmol) was added to a solution of Intermediate 22 (560 mg, 1.93 mmol) in PhMe (10 mL) and the reaction mixture was allowed to stir at room temperature for 2 hours. Then 4-fluoro-N'-Hydroxybenzimidamide (447 mg, 2.90 mmol) was added and the reaction mixture was allowed to stir for 1 hour at room temperature and for 17 hours at 110 ºC. The solvent was evaporated in high vacuum and the resulting residue was purified by column chromatography (silica gel, Petrol ether/EtOAc 3:1) in order to obtain compound 19 as an off-white solid (327 mg, 42%). [00230] HPLC-MS [M+H] + 409.21; MP: 145-147 ºC; 1 H NMR (400 MHz, CDCl 3 ) δ 8.13 – 8.03 (m, 2H), 7.90 (d, J = 9.2 Hz, 1H), 7.67 (dd, J = 7.5, 1.4 Hz, 1H), 7.52 (dd, J = 8.0, 1.4 Hz, 1H), 7.21 – 7.09 (m, 3H), 7.06 (d, J = 9.1 Hz, 1H), 4.65 (dt, J = 13.6, 3.9 Hz, 2H), 3.40 – 3.26 (m, 3H), 2.30 (dt, J = 13.5, 3.7 Hz, 2H), 2.16 – 2.01 (m, 2H); 13 C NMR (101 MHz, CDCl 3 ) δ 181.52, 167.46, 165.78, 163.29, 157.02, 143.99, 137.95, 130.50, 129.64, 126.14, 124.04, 122.10, 116.13, 115.91, 110.12, 44.48, 34.83, 29.02. [00231] In an embodiment, the method of synthesizing compound 20 (3-(pyridin-3-yl)-5-(1-(8-(pyridin-4- yl)quinolin-2-yl)piperidin-4-yl)-1,2,4-oxadiazole hydrochloride) is as follows:
[00232] In an embodiment, preparation of intermediate 23 (Ethyl 1-(8-bromoquinolin-2-yl)piperidine-4- carboxylate) was performed. DIPEA (5 ml) was added to a suspension of 8-bromo-2-chloroquinoline (1 g, 6.2 mmol) and ethyl isonipecotate (1.9 g, 12.3 mmol) in 1-BuOH (20 ml) and the mixture was allowed to stir at 130 ºC over a duration of 20 hours. The solvent was evaporated, and the resulting residue was purified by column chromatography (silica gel, Petrol ether/EtOAc 4:1) in order to obtain the title Intermediate 23 as a yellow solid (1.2 g, 54%). [00233] In an embodiment, preparation of intermediate 24 (ethyl 1-(8-(pyridin-4-yl)quinolin-2- yl)piperidine-4-carboxylate) was performed. Tetrakis(triphenylphosphine)palladium(0) (192 mg, 0.15 mmol) was added to a stirring suspension of intermediate 23 (1.2 g, 3.3 mmol), pyridine-4-ylboronic acid (450 mg, 3.7 mmol) and caesium carbonate (6 ml, 3M aqueous solution) in a mixture of 1,4-dioxane (30 ml) and water (5 ml). The suspension was allowed to stir at 80 ºC for a duration of 20 hours. The solvent was evaporated in high vacuum and the residue was purified by column chromatography (silica gel, Petrol ether/EtOAc 4:1). Intermediate 24 was isolated as a yellow solid (1.2 g, 89%). [00234] In an embodiment, preparation of intermediate 25 (1-(8-(pyridin-4-yl)quinolin-2-yl)piperidine-4- carboxylic acid) was performed. Potassium hydroxide (60 mL, 5N aqueous solution) was added to a solution of Intermediate 24 (1.2 g, 3.3 mmol) in 1,4-dioxane (60 ml). The mixture was allowed to stir at 80 ºC over a duration of 3.5 hours. The organic solvent was evaporated and the resulting aqueous mixture was acidified with acetic acid to pH1. The precipitate was separated by filtration and Intermediate 25 was obtained as a dark yellow solid (698 mg, 64%). [00235] In an embodiment, preparation of compound 20 (3-(pyridin-3-yl)-5-(1-(8-(pyridin-4-yl)quinolin-2- yl)piperidin-4-yl)-1,2,4-oxadiazole hydrochloride) was performed. CDI (511 mg, 3.15 mmol) was added to a solution of Intermediate 25 (698 mg, 2.1 mmol) in PhMe (10 mL) and the reaction mixture was allowed to stir at room temperature for 2 hours. Then (Z)-N'-hydroxynicotinimidamide (432 mg, 3.15 mmol) was added and the reaction mixture was allowed to stir for 1 hour at room temperature and for 20 hours at 110 ºC. The solvent was evaporated in high vacuum and the resulting residue was purified by column chromatography (silica gel, DCM/MeOH 2%). The product was dissolved in EtOAc (5 mL) and a 2M solution of hydrochloric acid in diethyl ether (1 mL) was added dropwise a 0 °ºC. The precipitate was separated by filtration and was washed with cold EtOAc. Compound 20 was isolated as a yellow solid (456 mg, 46%). [00236] HPLC-MS [M+H] + 435.27; MP: 273-277 ºC; 1 H NMR (400 MHz, DMSO-d 6 ) δ 9.23 (bs, 1H), 9.03 – 8.96 (m, 2H), 8.90 (dd, J = 5.1, 1.6 Hz, 1H), 8.59 (dt, J = 8.1, 1.9 Hz, 1H), 8.55 – 8.48 (m, 2H), 8.22 (d, J = 9.3 Hz, 1H), 7.97 (dd, J = 8.0, 1.5 Hz, 2H), 7.92 (dd, J = 7.4, 1.5 Hz, 1H), 7.83 (dd, J = 8.1, 5.1 Hz, 1H), 7.49 – 7.39 (m, 2H), 4.44 (dt, J = 13.7, 3.8 Hz, 2H), 3.60 (tt, J = 10.9, 4.0 Hz, 1H), 3.30 (ddd, J = 13.8, 11.3, 2.7 Hz, 2H), 2.22 (dd, J = 13.7, 3.8 Hz, 2H), 1.94 – 1.79 (m, 2H); 13 C NMR (101 MHz, DMSO-d 6 ) δ 183.13, 165.55, 157.44, 157.30, 149.93, 145.56, 144.54, 140.72, 138.82, 138.11, 132.18, 131.63, 130.44, 128.31, 126.10, 124.08, 123.54, 122.46, 111.42, 44.38, 34.18, 28.88. [00237] In an embodiment, the method of synthesizing compound 21 (5-(1-(6-methoxyquinolin-2- yl)piperidin-4-yl)-3-(pyridin-3-yl)-1,2,4-oxadiazole) is as follows: [00238] In an embodiment, preparation of Intermediate 26 (ethyl 1-(6-methoxyquinolin-2-yl)piperidine- 4-carboxylate) was performed. DIPEA (5 ml) was added to a suspension of 2-Chloro-6-methoxyquinoline (1 g, 5.2 mmol) and ethyl isonicotinate (972 mg, 6.2 mmol) in 1-BuOH (20 ml) and the mixture was allowed to stir at 130 ºC for 20 hours. The solvent was evaporated and the resulting residue was purified by column chromatography (silica gel, Petrol ether/EtOAc 4:1) and intermediate 26 was isolated as an off-white solid (900 mg, 55%). [00239] In an embodiment, preparation of intermediate 27 (1-(6-methoxyquinolin -2-yl)piperidine-4- carboxylic acid) was performed. A 5N aqueous solution of potassium hydroxide (20 ml) was added to a solution of Intermediate 26 (900 mg, 2.86 mmol) in 1,4-dioxane (20 ml). The solution was allowed to stir at 80 ºC over a duration of 2 hours. The solvent was evaporated in vacuum and the mixture was acidified to pH 1 with hydrochloric acid at 0 ºC. The precipitate was separated by filtration and was washed with water. The intermediate 27 was isolated as an off-white solid (1.02 g). [00240] In an embodiment, preparation of compound 21 (5-(1-(6-methoxyquinolin-2-yl)piperidin-4-yl)-3- (pyridin-3-yl)-1,2,4-oxadiazole) was performed. CDI (356 mg, 2.97 mmol) was added to a solution of Intermediate 27 (567 mg, 1.98 mmol) in PhMe (9 mL) and the reaction mixture was allowed to stir at room temperature for 2 hours. Then N'-Hydroxynicotinimidamide (410 mg, 2.97 mmol) was added and the reaction mixture was allowed to stir for 1 hour at room temperature and for 23 hours at 110 ºC. The solvent was evaporated in high vacuum and the resulting residue was purified by column chromatography (silica gel, Petrol ether/EtOAc 1:2) and compound 21 was isolated as an off-white solid (199 mg, 26%). [00241] HPLC-MS [M+H] + 388.24; MP: 185-186 ºC; 1 H NMR (400 MHz, DMSO-d 6 ) δ 9.17 (bs, 1H), 8.82 – 8.76 (m, 1H), 8.36 (dt, J = 8.0, 1.9 Hz, 1H), 8.27 (d, J = 9.3 Hz, 1H), 7.80 (d, J = 8.6 Hz, 1H), 7.62 (ddd, J = 8.0, 4.8, 0.9 Hz, 1H), 7.54 (d, J = 9.6 Hz, 1H), 7.41 – 7.34 (m, 2H), 4.47 (dt, J = 13.7, 3.8 Hz, 2H), 3.86 (s, 3H), 3.66 – 3.57 (m, 1H), 3.54 – 3.44 (m, 2H), 2.30 (dd, J = 13.5, 3.8 Hz, 2H), 2.06 – 1.92 (m, 2H); 13 C NMR (101 MHz, DMSO-d 6 ) δ 182.51, 166.22, 156.09, 152.76, 148.11, 135.09, 124.83, 122.95, 122.48, 108.21, 55.99, 45.77, 33.54, 28.78. [00242] In an embodiment, the method of synthesizing compound 22 (5-(1-(6-methoxyquinolin-2- yl)piperidin-4-yl)-3-(4-(trifluoromethoxy)phenyl)-1,2,4-oxad iazole) is as follows: [00243] In an embodiment, preparation of compound 22 (5-(1-(6-methoxyquinolin-2-yl)piperidin-4-yl)-3- (4-(trifluoromethoxy)phenyl)-1,2,4-oxadiazole) was performed. CDI (290 mg, 2.4 mmol) was added to a solution of Intermediate 27 (454 mg, 1.6 mmol) in PhMe (7 mL) and the reaction mixture was allowed to stir at room temperature for 2 hours. Then 4-(Trifluoromethoxy)benzamidoxime (340 mg, 2.4 mmol) was added and the reaction mixture was allowed to stir for 1 hour at room temperature and for 23 hours at 110 ºC. The solvent was evaporated in high vacuum and the resulting residue was purified by column chromatography (silica gel, Petrol ether/EtOAc 4:1) and compound 22 was isolated as a pale brown solid (100 mg, 13%). [00244] HPLC-MS [M+H] + 471.18; MP: 151-153 ºC; 1 H NMR (400 MHz, CDCl 3 ) δ 8.12 (d, J = 8.6 Hz, 2H), 7.96 – 7.86 (m, 2H), 7.31 (d, J = 8.4 Hz, 3H), 7.05 (d, J = 9.3 Hz, 1H), 7.01 – 6.96 (m, 1H), 4.49 (dt, J = 13.8, 4.4 Hz, 2H), 3.88 (s, 3H), 3.45 – 3.31 (m, 3H), 2.35 – 2.31 (m, 2H), 2.16 – 2.09 (m, 2H); 13 C NMR (101 MHz, CDCl 3 ) δ 181.29, 167.29, 161.91, 156.10, 151.27, 130.80, 129.20, 125.36, 123.00, 122.37, 122.33, 121.09, 121.00, 119.72, 110.62, 106.54, 55.60, 45.81, 34.25, 28.94. [00245] In an embodiment, the method of synthesizing compound 23 (5-(1-(8-methoxyquinolin-2- yl)piperidin-4-yl)-3-(4-nitrophenyl)-1,2,4-oxadiazole) is as follows: [00246] In an embodiment, preparation of compound 23 (5-(1-(8-methoxyquinolin-2-yl)piperidin-4-yl)-3- (4-nitrophenyl)-1,2,4-oxadiazole) was performed. CDI (440 mg, 2.7 mmol) was added to a solution of Intermediate 18 (700 mg, 2.44 mmol) in PhMe (10 mL) and the reaction mixture was allowed to stir at room temperature for 2 hours. Then 4-nitrobenzamidoxime (580 mg, 3.2 mmol) was added and the reaction mixture was allowed to stir for 1 hour at room temperature and for 23 hours at 110 ºC. The solvent was evaporated in high vacuum and the resulting residue was purified by column chromatography (silica gel, DCM/MeOH 5%) and compound 23 was isolated as an orange solid (513 mg, 49%). [00247] HPLC-MS [M+H] + 432.18; MP: 145-147 ºC; 1 H NMR (400 MHz, DMSO-d 6 ) δ 8.43 – 8.35 (m, 2H), 8.31 – 8.22 (m, 2H), 8.02 (d, J = 9.2 Hz, 1H), 7.34 – 7.24 (m, 2H), 7.15 (t, J = 7.8 Hz, 1H), 7.04 (dd, J = 7.8, 1.3 Hz, 1H), 4.57 (dt, J = 13.3, 3.8 Hz, 2H), 3.91 (s, 3H), 3.53 (tt, J = 11.0, 3.9 Hz, 1H), 3.27 – 3.15 (m, 2H), 2.28 – 2.19 (m, 2H), 1.94 – 1.79 (m, 2H); 13 C NMR (101 MHz, DMSO-d 6 ) δ 183.33, 166.67, 156.50, 153.71, 149.59, 139.20, 137.93, 132.51, 128.88, 124.91, 123.92, 122.41, 119.79, 110.70, 109.76, 56.12, 44.42, 34.35, 28.95. [00248] In an embodiment, the method of synthesizing compound 24 (4-(5-(1-(8-methoxyquinolin-2- yl)piperidin-4-yl)-1,2,4-oxadiazol-3-yl)phenol) is as follows:
[00249] In an embodiment, preparation of compound 24 (4-(5-(1-(8-methoxyquinolin-2-yl)piperidin-4-yl)- 1,2,4-oxadiazol-3-yl)phenol) was performed. CDI (400 mg, 2.39 mmol) was added to a solution of Intermediate 18 (500 mg, 1.75 mmol) in PhMe (10 mL) and the reaction mixture was allowed to stir at room temperature for 2 hours. Then 4-hydroxy-benzamidine oxime (242 mg, 1.59 mmol) was added and the reaction mixture was allowed to stir for 1 hour at room temperature and for 4 hours at 110 ºC. Water was added to the reaction mixture and the product was extracted with EtOAc. The organic layer was separated, dried over anhydrous sodium sulphate, was filtered and evaporated in high vacuum. The resulting residue was purified by column chromatography (silica gel, DCM/MeOH 5%) and compound 24 was isolated as an off-white solid (146 mg, 23%). [00250] HPLC-MS [M+H] + 403.19; MP: 200-203 ºC; 1 H NMR (400 MHz, DMSO-d 6 ) δ 10.12 (bs, 1H), 8.02 (d, J = 9.2 Hz, 1H), 7.87 – 7.79 (m, 2H), 7.31 – 7.26 (m, 2H), 7.15 (t, J = 7.9 Hz, 1H), 7.04 (dd, J = 7.8, 1.3 Hz, 1H), 6.95 – 6.86 (m, 2H), 4.56 (dt, J = 13.2, 3.9 Hz, 2H), 3.90 (s, 3H), 3.43 (tt, J = 12.5, 4.6 Hz, 1H), 3.19 (ddd, J = 13.9, 11.9, 2.7 Hz, 2H), 2.19 (dd, J = 13.6, 3.7 Hz, 2H), 1.89 – 1.76 (m, 2H); 13 C NMR (101 MHz, DMSO- d 6 ) δ 181.98, 167.79, 160.71, 156.51, 153.72, 139.22, 137.92, 129.23, 123.91, 122.38, 119.79, 117.39, 116.38, 110.69, 109.77, 56.12, 44.47, 34.31, 29.08. [00251] In an embodiment, the method of synthesizing compound 25 (5-(1-(8-methoxyquinolin-2- yl)piperidin-4-yl)-3-(pyridin-2-yl)-1,2,4-oxadiazole hydrochloride) is as follows: [00252] In an embodiment, preparation of compound 25 (5-(1-(8-methoxyquinolin-2-yl)piperidin-4-yl)-3- (pyridin-2-yl)-1,2,4-oxadiazole hydrochloride) was performed. CDI (640 mg, 3.85 mmol) was added to a solution of Intermediate 18 (1 g, 3.5 mmol) in PhMe (15 mL) and the reaction mixture was allowed to stir at room temperature for 2 hours. Then Pyridine-2-carboxamide oxime (630 mg, 4.55 mmol) was added and the reaction mixture was allowed to stir for 1 hour at room temperature and for 7 hours at 110 ºC. The solvent was evaporated in high vacuum and the resulting residue was purified by column chromatography (silica gel, Petrol ether/EtOAc 2:1-1:2). The product was dissolved in EtOAc (5 mL) and a 2M solution of hydrochloric acid in diethyl ether (1 mL) was added dropwise a 0 ºC. The precipitate was separated by filtration and was washed with cold EtOAc. Compound 25 was isolated as an off-white solid (179 mg, 12%). [00253] HPLC-MS [M+H] + 388.2; MP: 60-64 ºC; 1 H NMR (400 MHz, MeOD-d 4 ) δ 8.77 – 8.70 (m, 1H), 8.46 (d, J = 9.7 Hz, 1H), 8.24 – 8.16 (m, 1H), 8.05 (td, J = 7.8, 1.7 Hz, 1H), 7.68 – 7.58 (m, 2H), 7.56 – 7.49 (m, 2H), 7.46 (dd, J = 6.1, 3.1 Hz, 1H), 4.48 (dt, J = 14.1, 4.2 Hz, 2H), 4.16 (s, 3H), 3.85 – 3.63 (m, 3H), 2.50 (dt, J = 13.0, 4.0 Hz, 2H), 2.32 – 2.18 (m, 2H); 13 C NMR (101 MHz, MeOD-d 4 ) δ 181.74, 167.67, 151.79, 149.69, 147.64, 145.75, 143.45, 137.87, 123.26, 121.92, 119.57, 117.36, 112.45, 55.79, 46.30, 32.92, 28.33. [00254] In an embodiment, the method of synthesizing compound 26 (3-(5-(1-(8-methoxyquinolin-2- yl)piperidin-4-yl)-1,2,4-oxadiazol-3-yl)pyridine 1-oxide) is as follows: [00255] In an embodiment, preparation of Intermediate 28 (2 (Z)-3-(N'-hydroxycarbamimidoyl)pyridine 1- oxide) was performed. Hydroxylamine hydrochloride (0.4 mL, 9.96 mmol) was added dropwise to a solution of nitrile starting material (1g, 8.3 mmol) in water (14 mL). Sodium hydrogencarbonate (840 mg, 9.96 mmol) was added and the mixture was allowed to stir at room temperature over a duration of 18 hours. The solid was separated by filtration and was washed with water to give crude Intermediate 28 as a colourless solid (1.36 g, 94%). [00256] In an embodiment, preparation of compound 26 (3-(5-(1-(8-methoxyquinolin-2-yl)piperidin-4-yl)- 1,2,4-oxadiazol-3-yl)pyridine 1-oxide) was performed. CDI (640 mg, 3.85 mmol) was added to a solution of Intermediate 18 (1 g, 3.5 mmol) in PhMe (15 mL) and the reaction mixture was allowed to stir at room temperature for 2 hours. Then Intermediate 28 (700 mg, 4.55 mmol) was added and the reaction mixture was allowed to stir for 1 hour at room temperature and for 7 hours at 110 ºC. The solvent was evaporated in high vacuum and the resulting residue was purified by column chromatography (silica gel, DCM/MeOH 5%) and the title and compound 26 was isolated as an off-white solid (157 mg, 11%). [00257] HPLC-MS [M+H] + 404.17; MP: 189-192 ºC; 1 H NMR (400 MHz, DMSO-d 6 ) δ 9.44 (bs, 1H), 9.23 (ddd, J = 6.5, 1.9, 0.9 Hz, 1H), 8.83 (d, J = 9.2 Hz, 1H), 8.68 (dt, J = 8.0, 1.2 Hz, 1H), 8.41 (dd, J = 8.0, 6.5 Hz, 1H), 8.14 – 8.05 (m, 2H), 7.95 (t, J = 7.8 Hz, 1H), 7.84 (dd, J = 7.8, 1.3 Hz, 1H), 5.37 (dt, J = 13.5, 3.8 Hz, 2H), 4.72 (s, 3H), 4.33 (tt, J = 11.1, 3.9 Hz, 1H), 4.08 – 3.96 (m, 2H), 3.03 (dd, J = 13.4, 3.7 Hz, 2H), 2.75 – 2.58 (m, 2H); 13 C NMR (101 MHz, DMSO-d 6 ) δ 183.39, 164.72, 156.48, 153.71, 141.57, 139.19, 137.94, 137.01, 127.91, 126.47, 123.92, 123.65, 122.41, 119.79, 110.69, 109.77, 56.12, 44.37, 34.33, 28.92. [00258] In an embodiment, the method of synthesizing compound 27 (3-(pyridin-3-yl)-5-(1-(6-(pyridin-4- yl)quinolin-2-yl)piperidin-4-yl)-1,2,4-oxadiazole) is as follows: [00259] In an embodiment, preparation of intermediate 29 (Ethyl 1-(6-bromoquinolin-2-yl)piperidine-4- carboxylate) was performed. DIPEA (28 ml) was added to a suspension of 6-bromo-2-chloroquinoline (10 g, 41.2 mmol) and ethyl isonipecotate (7.12 g, 45.3 mmol) in 1-BuOH (100 ml) and the mixture was allowed to stir at 130 ºC over a duration of 18 hours. The solvent was evaporated, and the resulting residue was purified by column chromatography (silica gel, Petrol ether/EtOAc 8:1-4:1) in order to obtain the title Intermediate 29 as a yellow solid (8.09 g, 55%). [00260] In an embodiment, preparation of intermediate 30 (ethyl 1-(6-(pyridin-4-yl)quinolin-2- yl)piperidine-4-carboxylate) was performed. Tetrakis(triphenylphosphine)palladium(0) (414 mg, 0.36 mmol) was added to a stirring suspension of intermediate 29 (2.6 g, 7.16 mmol), pyridine-4-ylboronic acid (970 mg, 7.87 mmol) and caesium carbonate (12 ml, 3M aqueous solution) in a mixture of 1,4-dioxane (40 ml) and water (9 ml). The suspension was allowed to stir at 80 ºC for a duration of 18 hours. The solvent was evaporated in high vacuum and the residue was purified by column chromatography (silica gel, Petrol ether/EtOAc 2:1-1:2) and the title intermediate 30 was isolated as a colourless solid (1.7 g, 71%). [00261] In an embodiment, preparation of intermediate 31 (1-(6-(pyridin-4-yl)quinolin-2-yl)piperidine-4- carboxylic acid) was performed. Potassium hydroxide (1.4 g, 23.5 mmol) was added to a solution of Intermediate 30 (1.7 g, 4.7 mmol) in a mixture of MeOH (34 mL) and water (3.4 ml). The mixture was allowed to stir at room temperature over a duration of 5 hours. The organic solvent was evaporated, water was added and the resulting aqueous mixture was acidified with acetic acid to pH4. No precipitate formed. The aqueous solution was extracted with EtOAc, the organic layer was dried with anhydrous sodium sulphate, was subsequently filtered and evaporated in high vacuum in order to obtain Intermediate 31 as a yellow solid (1.1 g, 70%). [00262] In an embodiment, preparation of Compound 27 (3-(pyridin-3-yl)-5-(1-(6-(pyridin-4-yl)quinolin-2- yl)piperidin-4-yl)-1,2,4-oxadiazole) was performed. CDI (1.3 g, 7.8 mmol) was added to a solution of Intermediate 31 (1.9 g, 5.7 mmol) in a mixture of PhMe (10 mL) and DMF (10 mL) and the reaction mixture was allowed to stir at 50 ºC for 15 minutes. Then N'-Hydroxynicotinimidamide (713 mg, 5.2 mmol) was added and the reaction mixture was allowed to stir at 100 ºC over a duration of 3 hours. The solvent was evaporated in high vacuum and the resulting residue was purified by column chromatography (silica gel, DCM/MeOH 5%) in order to obtain compound 27 as a yellow solid (570 mg, 23%). [00263] HPLC-MS [M+2H] 2+ 218.40; MP: 188-190 ºC; 1 H NMR (400 MHz, CDCl 3 ) δ 9.30 (bs, 1H), 8.74 (d, J = 6.5 Hz, 1H), 8.69 – 8.63 (m, 2H), 8.34 (dt, J = 8.0, 2.0 Hz, 1H), 7.98 (d, J = 9.2 Hz, 1H), 7.90 (d, J= 2.0 Hz, 1H), 7.85 – 7.76 (m, 2H), 7.62 – 7.57 (m, 2H), 7.46 – 7.37 (m, 1H), 7.09 (d, J = 9.2 Hz, 1H), 4.62 (dt, J = 13.7, 3.9 Hz, 2H), 3.43 – 3.26 (m, 3H), 2.31 (dd, J = 13.5, 3.8 Hz, 2H), 2.16 – 2.01 (m, 2H); 13 C NMR (101 MHz, CDCl 3 ) δ 177.15, 161.63, 152.69, 147.28, 145.46, 143.91, 143.59, 143.24, 133.21, 129.92, 127.00, 123.40, 122.73, 120.92, 118.88, 118.37, 118.27, 116.62, 105.57, 39.85, 30.10, 24.30. [00264] In an embodiment, the method of synthesizing compound 28 (5-(5-(1-(8-methoxyquinolin-2- yl)piperidin-4-yl)-1,2,4-oxadiazol-3-yl)-N-methylpyridin-2-a mine) is as follows: [00265] In an embodiment, preparation of Intermediate 32 ((Z)-N'-hydroxy-6- (methylamino)nicotinimidamide) was performed. Hydroxylamine hydrochloride (785 mg, 11.3 mmol) was slowly added to a solution of nitrile starting material (1g, 7.5 mmol) in ethanol (8 mL). Triethylamine (2.1 mL, 15 mmol) was added and the mixture was allowed to stir at room temperature over a duration of 23 hours. The solvent was removed under reduced pressure, the solids were washed with water and crude product was isolated as a colourless solid (2.06g). The crude intermediate 32 was used for the next step without further purification. [00266] In an embodiment, preparation of compound 28 (5-(5-(1-(8-methoxyquinolin-2-yl)piperidin-4-yl)- 1,2,4-oxadiazol-3-yl)-N-methylpyridin-2-amine) was performed. CDI (600 mg, 7.8 mmol) was added to a solution of Intermediate 18 (700 mg, 2.44 mmol) in a mixture of PhMe (10 mL) and DMF (5 mL) and the reaction mixture was allowed to stir at room temperature over a duration of 1 hour. Then intermediate 32 (610 mg, 3.67 mmol) was added and the reaction mixture was allowed to stir at 90 ºC over a duration of 5 hours. The solvent was evaporated in high vacuum and the resulting residue was purified by column chromatography (silica gel, Petrol ether/EtOAc 1:1) in order to obtain compound 28 as an off-white solid (317 mg, 35%). [00267] HPLC-MS [M+H] + 417.20; MP: 240-243 ºC; 1 H NMR (400 MHz, DMSO-d 6 ) δ 8.93 (bs, 1H), 8.38 (d, J = 10.8 Hz, 2H), 8.22 (bs, 1H), 7.63 (d, J = 9.6 Hz, 1H), 7.48 (d, J = 7.9 Hz, 1H), 7.45 – 7.33 (m, 2H), 7.22 (d, J = 9.3 Hz, 1H), 4.48 – 4.42 (m, 2H), 4.03 (s, 3H), 3.56 – 3.50 (m, 3H), 3.06 (s, 3H), 2.34 – 2.27 (m, 2H), 2.06 – 1.96 (m, 2H); 13 C NMR (101 MHz, DMSO-d 6 ) δ 182.28, 164.84, 155.09, 125.20, 122.57, 120.19, 113.30, 112.60, 111.12, 56.85, 46.58, 34.48, 33.19, 28.90. [00268] In an embodiment, the method of synthesizing compound 29 (5-(1-(8-methoxyquinolin-2- yl)piperidin-4-yl)-3-(3-nitrophenyl)-1,2,4-oxadiazole) is as follows: [00269] In an embodiment, preparation of Intermediate 33 ((Z)-N'-hydroxy-3-nitrobenzimidamide) was performed. Hydroxylamine hydrochloride (1.1 g, 16.2 mmol) was slowly added to a solution of nitrile starting material (2 g, 13.5 mmol) in a mixture of methanol (MeOH) (10 mL) and water (2 mL). Sodium hydrogencarbonate (1.4 g, 16.2 mmol) was added and the mixture was allowed to stir at 85 ºC over a duration of 5 hours. The reaction mixture was cooled down to 0 ºC, the precipitate was separated by filtration and was washed with water. Intermediate 33 was isolated as a yellow solid (2.42 g, 98%). [00270] In an embodiment, preparation of compound 29 (5-(1-(8-methoxyquinolin-2-yl)piperidin-4-yl)-3- (3-nitrophenyl)-1,2,4-oxadiazole) was performed. CDI (600 mg, 3.7 mmol) was added to a solution of Intermediate 18 (700 mg, 2.44 mmol) in a mixture of PhMe (10 mL) and DMF (5 mL) and the reaction mixture was allowed to stir at room temperature over a duration of 1 hour. Then intermediate 33 (560 mg, 3.68 mmol) was added and the reaction mixture was allowed to stir at 90 ºC over a duration of 5 hours. The solvent was evaporated in high vacuum and the resulting residue was purified by column chromatography (silica gel, Petrol ether/EtOAc 2:1) in order to obtain compound 29 as a yellow solid (189 mg, 18%). [00271] HPLC-MS [M+H] + 417.20; MP: 240-243 ºC; 1 H NMR (400 MHz, DMSO-d 6 ) δ 8.69 (bs, 1H), 8.50 – 8.38 (m, 2H), 8.02 (d, J = 9.1 Hz, 1H), 7.87 (t, J = 8.0 Hz, 1H), 7.34 – 7.20 (m, 2H), 7.15 (t, J = 7.8 Hz, 1H), 7.04 (dd, J = 7.8, 1.3 Hz, 1H), 4.57 (dt, J = 13.6, 3.8 Hz, 2H), 3.91 (s, 3H), 3.53 (tt, J = 11.1, 3.9 Hz, 1H), 3.21 (ddd, J = 13.8, 11.6, 2.7 Hz, 2H), 2.24 (dd, J = 13.6, 3.6 Hz, 2H), 1.95 – 1.80 (m, 2H); 13 C NMR (101 MHz, DMSO-d 6 ) δ 183.29, 166.55, 156.50, 153.73, 148.69, 139.23, 137.92, 133.52, 1310.65, 128.21, 126.53, 123.93, 122.40, 121.94, 119.79, 110.69, 109.81, 56.15, 44.42, 34.38, 28.97. [00272] In an embodiment, the method of synthesizing compound 30 (5-(5-(1-(8-methoxyquinolin-2- yl)piperidin-4-yl)-1,2,4-oxadiazol-3-yl)pyridin-2-amine hydrochloride) is as follow: [00273] In an embodiment, preparation of Intermediate 34 ((Z)-6-amino-N'-hydroxynicotinimidamide) was performed. Hydroxylamine hydrochloride (830 mg, 12.6 mmol) was slowly added to a solution of nitrile starting material (1 g, 8.4 mmol) in MeOH (10 mL). A solution of sodium hydrogencarbonate (1.8 g, 16.8 mmol) in water (5.5 mL) was added and the mixture was allowed to stir at 85 ºC over a duration of 24 hours. The reaction mixture was cooled down to 0 ºC, the precipitate was separated by filtration and was washed with water. Intermediate 34 was isolated as a colourless solid (2.1 g). [00274] In an embodiment, preparation of compound 30 (5-(5-(1-(8-methoxyquinolin-2-yl)piperidin-4-yl)- 1,2,4-oxadiazol-3-yl)pyridin-2-amine hydrochloride) was performed. CDI (595 mg, 3.66 mmol) was added to a solution of Intermediate 18 (700 mg, 2.44 mmol) in a mixture of PhMe (10 mL) and DMF (5 mL) and the reaction mixture was allowed to stir at room temperature over a duration of 1 hour. Then intermediate 34 (560 mg, 3.66 mmol) was added and the reaction mixture was allowed to stir at 90 ºC over a duration of 5 hours. The solvent was evaporated in high vacuum and the resulting residue was purified by column chromatography (silica gel, Petrol ether/EtOAc, 1:2) in order to obtain compound 30 as a clear oil. The product was dissolved in EtOAc (5 mL) and a 2M solution of hydrochloric acid in diethyl ether (2.5 mL) was added dropwise a 0 ºC. The precipitate was separated by filtration and was washed with cold diethyl ether. Compound 30 was isolated as an off-white solid (39.5 mg, 4%). [00275] HPLC-MS [M+H] + 403.20; MP: not applicable (oil); 1 H NMR (400 MHz, DMSO-d 6 ) δ 8.78 (bs, 2H), 8.52 (bs, 1H), 8.31 (dt, J = 9.3, 2.4 Hz, 2H), 7.57 (d, J = 9.6 Hz, 1H), 7.45 (dd, J = 7.9, 1.4 Hz, 1H), 7.41 – 7.27 (m, 2H), 7.15 (d, J = 9.3 Hz, 1H), 4.50 – 4.42 (m, 2H), 4.01 (s, 3H), 3.64 – 3.57 (s, 1H), 3.12 – 3.00 (m, 2H), 2.27 (dd, J = 13.7, 3.9 Hz, 2H), 2.04 – 1.89 (m, 2H); 13 C NMR (101 MHz, DMSO-d 6 ) δ 182.41, 164.78, 155.78, 140.55, 136.99, 122.80, 120.11, 114.70, 111.55, 56.71, 46.16, 45.79, 34.53, 33.37, 28.88, 8.88. [00276] In an embodiment, the method of synthesizing compound 31 (3-(6-chloropyridin-3-yl)-5-(1-(8- methoxyquinolin-2-yl)piperidin-4-yl)-1,2,4-oxadiazole hydrochloride) is as follow: [00277] In an embodiment, preparation of Intermediate 35 ((Z)-6-chloro-N'-hydroxynicotinimidamide) was performed. Hydroxylamine hydrochloride (1.2 g, 17 mmol) was slowly added to a solution of nitrile starting material (2 g, 14 mmol) in a mixture of MeOH (20 mL) and water (4 mL). Sodium hydrogencarbonate (1.4 g, 17 mmol) was added and the mixture was allowed to stir at 85 ºC over a duration of 2 hours. The reaction mixture was cooled down to 0 ºC, the precipitate was separated by filtration and was washed with water. Intermediate 35 was isolated as a colourless solid (1.97 g, 82%). [00278] In an embodiment, preparation of compound 31 (3-(6-chloropyridin-3-yl)-5-(1-(8- methoxyquinolin-2-yl)piperidin-4-yl)-1,2,4-oxadiazole hydrochloride) was performed. CDI (852 mg, 5.24 mmol) was added to a solution of Intermediate 18 (1.4 g, 4.4 mmol) in a mixture of PhMe (20 mL) and DMF (1 mL) and the reaction mixture was allowed to stir at room temperature over a duration of 1 hour. Then intermediate 35 (900 mg, 5.24 mmol) was added and the reaction mixture was allowed to stir at 80 ºC over a duration of 18 hours. The solvent was evaporated in high vacuum and the resulting residue was purified by column chromatography (silica gel, Petrol ether/EtOAc 2:1) in order to obtain compound 31 as a clear oil. The product was dissolved in EtOAc (10 mL) and a 2M solution of hydrochloric acid in diethyl ether (2 mL) was added dropwise a 0 ºC. The precipitate was separated by filtration and was washed with cold diethyl ether. Compound 31 was isolated as a colourless solid (430 mg, 23%). [00279] HPLC-MS [M+H] + 422.25; MP: 217-218 ºC; 1 H NMR (400 MHz, DMSO-d 6 ) δ 8.99 (bs, 1H), 8.40 (dd, J = 8.4, 2.4 Hz, 1H), 8.36 (d, J = 9.1 Hz, 1H), 7.75 (dd, J = 8.3, 0.7 Hz, 1H), 7.61 (d, J = 9.6 Hz, 1H), 7.47 (d, J = 7.7 Hz, 1H), 7.44 – 7.33 (m, 2H), 4.46 (dt, J = 14.2, 3.8 Hz, 2H), 4.03 (s, 3H), 3.70 – 3.65 (m, 1H), 3.58 – 3.47 (m, 2H), 2.36 – 2.26 (m, 2H), 2.08 – 1.94 (m, 2H); 13 C NMR (101 MHz, DMSO-d 6 ) δ 182.68, 165.47, 153.35, 148.54, 138.45, 125.63, 122.68, 122.45, 120.16, 56.79, 46.37, 33.31, 28.88. [00280] In an embodiment, the method of synthesizing compound 32 (5-(1-(8-methoxyquinolin-2- yl)piperidin-4-yl)-3-(pyrimidin-2-yl)-1,2,4-oxadiazole) is as follow: [00281] In an embodiment, preparation of Intermediate 36 ((Z)-N'-hydroxypyrimidine-2- carboximidamide) was performed. Hydroxylamine hydrochloride (390 mg, 5.7 mmol) was slowly added to a solution of nitrile starting material (0.5 g, 4.7 mmol) in a mixture of MeOH (5 mL) and water (1 mL). Sodium hydrogencarbonate (470 mg, 5.7 mmol) was added and the mixture was allowed to stir at room temperature for 1h and at 85 ºC over a duration of 20 hours. The reaction mixture was evaporated in vacuum and the resulting residue was suspended in water and was filtered. Intermediate 36 was isolated as a colourless solid (447 mg, 68%). [00282] In an embodiment, preparation of compound 32 (5-(1-(8-methoxyquinolin-2-yl)piperidin-4-yl)-3- (pyrimidin-2-yl)-1,2,4-oxadiazole) was performed. CDI (510 mg, 3.2 mmol) was added to a solution of Intermediate 18 (600 mg, 2.1 mmol) in a mixture of PhMe (9 mL) and DMF (4 mL) and the reaction mixture was allowed to stir at room temperature over a duration of 1 hours. Then intermediate 36 (440 mg, 3.2 mmol) was added and the reaction mixture was allowed to stir at 90 ºC over a duration of 2 hours. The solvent was evaporated in high vacuum and the resulting residue was purified by column chromatography (silica gel, DCM/MeOH 2%) in order to obtain compound 32 as an off-white solid (270 mg, 33%). [00283] HPLC-MS [M+H] + 389.12; MP: 167-169 ºC; 1 H NMR (500 MHz, DMSO-d 6 ) δ 9.05 – 9.00 (m, 2H), 8.02 (d, J = 9.2 Hz, 1H), 7.75 – 7.68 (m, 1H), 7.33 – 7.23 (m, 2H), 7.14 (t, J = 7.8 Hz, 1H), 7.03 (dd, J = 7.8, 1.4 Hz, 1H), 4.56 (dt, J = 13.4, 3.7 Hz, 2H), 3.91 (s, 3H), 3.51 (tt, J = 11.1, 3.9 Hz, 1H), 3.20 (ddd, J = 13.7, 11.5, 2.7 Hz, 2H), 2.24 (dd, J = 13.5, 3.6 Hz, 2H), 1.92 – 1.80 (m, 2H); 13 C NMR (126 MHz, DMSO-d 6 ) δ 183.23, 167.75, 158.67, 156.56, 155.88, 153.75, 139.24, 137.92, 123.95, 123.27, 122.41, 119.80, 110.72, 109.82, 56.16, 44.45, 34.37, 28.98. [00284] In an embodiment, the method of synthesizing compound 33 (5-(1-(8-methoxyquinolin-2- yl)piperidin-4-yl)-3-(6-(piperidin-1-yl)pyridin-3-yl)-1,2,4- oxadiazole) is as follow: [00285] In an embodiment, preparation of compound 33 (5-(1-(8-methoxyquinolin-2-yl)piperidin-4-yl)-3- (6-(piperidin-1-yl)pyridin-3-yl)-1,2,4-oxadiazole) was performed. Piperidine (0.2 mL, 1.54 mmol) was added to a stirring dispersion of Compound 31 (300 mg, 0.7 mmol) and potassium carbonate (213 mg, 1.54 mmol) in THF (5 mL) at room temperature. The mixture was allowed to stir at 50 ºC over a duration of 20 hours. The solvent was evaporated in high vacuum and the residue was dissolved in EtOAc and was washed with water, followed by brine. The organic layer was separated, dried over anhydrous sodium sulphate, was filtered and evaporated in high vacuum to give an oily solid. The solid was triturated with diethylether and was separated by filtration. Compound 33 was isolated as an off-white solid (247 mg, 75%). [00286] HPLC-MS [M+H] + 471.20; MP: 165-166 ºC; 1 H NMR (400 MHz, CDCl 3 ) δ 8.83 (bs, 1H), 8.03 (dd, J = 9.0, 2.4 Hz, 1H), 7.90 (d, J = 9.1 Hz, 1H), 7.26 – 7.12 (m, 2H), 7.05 (d, J = 9.1 Hz, 1H), 6.96 (dd, J = 7.6, 1.4 Hz, 1H), 6.67 (d, J = 9.0 Hz, 1H), 4.58 (dt, J = 13.5, 3.8 Hz, 2H), 4.03 (s, 3H), 3.68 – 3.60 (m, 4H), 3.33 – 3.18 (m, 3H), 2.29 (dt, J = 13.7, 3.6 Hz, 2H), 2.14 – 2.02 (m, 2H), 1.69 – 1.63 (m, 6H); 13 C NMR (101 MHz, CDCl 3 ) δ 180.97, 166.86, 160.15, 156.78, 153.55, 147.97, 139.24, 137.67, 135.98, 123.96, 122.27, 119.45, 110.92, 110.05, 108.74, 105.95, 56.14, 45.96, 44.77, 34.87, 29.25, 25.53, 24.70. [00287] In an embodiment, the method of synthesizing compound 34 (5-(1-(8-methoxyquinolin-2- yl)piperidin-4-yl)-3-(6-(piperazin-1-yl)pyridin-3-yl)-1,2,4- oxadiazole) is as follow: [00288] In an embodiment, preparation of compound 34 (5-(1-(8-methoxyquinolin-2-yl)piperidin-4-yl)-3- (6-(piperazin-1-yl)pyridin-3-yl)-1,2,4-oxadiazole) was performed. Piperazine (603 mg, 7 mmol) was added to a stirring dispersion of Compound 31 (300 mg, 0.7 mmol) and DIPEA (0.2 mL, 1.4 mmol) in 1,4-dioxane (6 mL) at room temperature. The mixture was allowed to stir at reflux over a duration of 12 hours. The solvent was evaporated in high vacuum and the resulting oily solid was triturated with diethylether and was separated by filtration. Compound 34 was isolated as an off-white solid (295 mg, 89%). [00289] HPLC-MS [M+2H] 2+ 236.67; MP: 107-109 ºC; 1 H NMR (400 MHz, CDCl 3 ) δ 8.85 (bs, 1H), 8.07 (d, J = 6.6 Hz, 1H), 7.89 (d, J = 9.1 Hz, 1H), 7.21 (d, J = 8.0 Hz, 1H), 7.16 (t, J = 7.7 Hz, 1H), 7.05 (d, J = 9.1 Hz, 1H), 6.96 (d, J = 7.6 Hz, 1H), 6.66 (d, J = 9.0 Hz, 1H), 4.57 (dt, J = 13.2, 4.0 Hz, 2H), 4.02 (s, 3H), 3.62 (t, J = 5.0 Hz, 4H), 3.28 – 3.21 (m, 3H), 2.97 (t, J = 5.0 Hz, 4H), 2.85 (bs, 1H), 2.30 – 2.25 (m, 2H), 2.10 – 2.03 (m, 2H); 13 C NMR (101 MHz, CDCl 3 ) δ 181.12, 166.75, 160.33, 156.78, 153.54, 147.85, 139.23, 137.70, 136.13, 123.97, 122.30, 119.47, 111.86, 110.06, 108.75, 106.02, 56.15, 45.91, 45.89, 44.77, 34.88, 29.26. [00290] In an embodiment, the method of synthesizing compound 35 (2-((5-(5-(1-(8-methoxyquinolin-2- yl)piperidin-4-yl)-1,2,4-oxadiazol-3-yl)pyridin-2-yl)amino)e than-1-ol hydrochloride) is as follow: [00291] In an embodiment, preparation of compound 35 (2-((5-(5-(1-(8-methoxyquinolin-2-yl)piperidin-4- yl)-1,2,4-oxadiazol-3-yl)pyridin-2-yl)amino)ethan-1-ol hydrochloride) was performed. Ethanolamine (0.3 mL, 5 mmol) was added to a stirring dispersion of Compound 31 (200 mg, 0.5 mmol) and DIPEA (0.2 mL, 1 mmol) in 1,4-dioxane (6 mL) at room temperature. The mixture was allowed to stir at reflux over a duration of 12 hours. The solvent was evaporated in high vacuum and the product was purified by preparative TLC (DCM/MeOH 5%). The resulting oil was dissolved in DCM (5 mL) and a 2M solution of hydrochloric acid in diethyl ether (1 mL) was added dropwise a 0 ºC. The precipitate was separated by filtration and was washed with cold diethyl ether. Compound 35 was isolated as a colourless solid (127 mg, 53%). [00292] HPLC-MS [M+H] + 447.30; MP: 228-231 ºC; 1 H NMR (400 MHz, DMSO-d 6 ) δ 9.27 (bs, 1H), 8.38 (bs, 1H), 8.31 (d, J = 9.5 Hz, 1H), 8.18 (dd, J = 9.4, 2.2 Hz, 1H), 7.56 (d, J = 9.5 Hz, 1H), 7.44 (d, J = 7.9 Hz, 1H), 7.40 – 7.26 (m, 2H), 7.17 (d, J = 9.3 Hz, 1H), 4.51 – 4.40 (m, 2H), 4.00 (s, 3H), 3.64 – 3.41 (m, 7H), 2.27 (dd, J = 13.9, 3.9 Hz, 2H), 2.04 – 1.89 (m, 2H). 13 C NMR (101 MHz, DMSO-d 6 ) δ 182.25, 165.03, 122.80, 120.11, 112.84, 112.23, 111.09, 59.58, 56.71, 46.18, 45.24, 33.39, 28.92. [00293] In an embodiment, the method of synthesizing compound 36 (5-(5-(1-(8-methoxyquinolin-2- yl)piperidin-4-yl)-1,2,4-oxadiazol-3-yl)pyridin-3-ol) is as follow: [00294] In an embodiment, preparation of Intermediate 37 ((Z)-N',5-dihydroxynicotinimidamide) was performed. Hydroxylamine hydrochloride (695 mg, 10 mmol) was slowly added to a solution of nitrile starting material (1 g, 8.33 mmol) in a mixture of MeOH (10 mL) and water (1 mL). Sodium hydrogencarbonate (840 mg, 10 mmol) was added and the mixture was allowed to stir at 60 ºC over a duration of 3 hours. The reaction mixture was evaporated in vacuum and the resulting residue was suspended in water and was filtered. Intermediate 37 was isolated as a colourless solid (1.01 g, 79%). [00295] In an embodiment, preparation of compound 36 (5-(5-(1-(8-methoxyquinolin-2-yl)piperidin-4-yl)- 1,2,4-oxadiazol-3-yl)pyridin-3-ol) was performed. CDI (566 mg, 3.5 mmol) was added to a solution of Intermediate 18 (700 mg, 2.9 mmol) in a mixture of PhMe (10 mL) and DMF (2 mL) and the reaction mixture was allowed to stir at room temperature over a duration of 1 hour. Then intermediate 37 (536 mg, 3.5 mmol) was added and the reaction mixture was allowed to stir at room temperature for 30 minutes and at 100 ºC over a duration of 5 hours. The solvent was evaporated in high vacuum and the resulting residue was purified by column chromatography (silica gel, EtOAc) in order to obtain compound 36 as a colourless solid (272 mg, 23%). [00296] HPLC-MS [M+H] + 404.16; MP: 202-204 ºC; 1 H NMR (400 MHz, DMSO-d 6 ) δ 10.43 (bs, 1H), 8.63 (bs, 1H), 8.32 (bs, 1H), 8.02 (d, J = 9.2 Hz, 1H), 7.73 – 7.67 (m, 1H), 7.34 – 7.24 (m, 2H), 7.15 (td, J = 7.8, 1.6 Hz, 1H), 7.04 (dd, J = 7.8, 1.4 Hz, 1H), 4.57 (dt, J = 13.4, 3.8 Hz, 2H), 3.91 (s, 3H), 3.50 (tt, J = 11.1, 3.8 Hz, 1H), 3.20 (ddd, J = 13.7, 11.6, 2.7 Hz, 2H), 2.22 (dd, J = 13.4, 3.8 Hz, 2H), 1.92 – 1.77 (m, 2H); 13 C NMR (101 MHz, DMSO-d 6 ) δ 182.84, 166.20, 156.50, 154.30, 153.71, 141.45, 139.21, 138.76, 137.92, 123.92, 123.40, 122.40, 120.12, 119.79, 110.69, 109.77, 56.12, 44.41, 34.34, 28.99. [00297] In an embodiment, the method of synthesizing compound 37 (2 5-(1-(8-methoxyquinolin-2- yl)piperidin-4-yl)-3-(1H-pyrrolo[2,3-b]pyridin-5-yl)-1,2,4-o xadiazole) is as follow: [00298] In an embodiment, preparation of Intermediate 38 (Z)-N'-hydroxy-1H-pyrrolo[2,3-b]pyridine-5- carboximidamide) was performed. Hydroxylamine hydrochloride (585 mg, 8.4 mmol) was slowly added to a solution of nitrile starting material (1 g, 7 mmol) in a mixture of MeOH (10 mL) and water (1 mL). Sodium hydrogencarbonate (710 mg, 8.4 mmol) was added and the mixture was allowed to stir at 60 ºC over a duration of 4 hours. The reaction mixture was evaporated in vacuum and the resulting residue was suspended in water and was filtered. Intermediate 38 was isolated as off-white solid (1.02 g, 83%). [00299] In an embodiment, preparation of compound 37 (25-(1-(8-methoxyquinolin-2-yl)piperidin-4-yl)- 3-(1H-pyrrolo[2,3-b]pyridin-5-yl)-1,2,4-oxadiazole) was performed. CDI (476 mg, 2.93 mmol) was added to a solution of Intermediate 18 (700 mg, 2.4 mmol) in a mixture of PhMe (10 mL) and DMF (2 mL) and the reaction mixture was allowed to stir at room temperature over a duration of 1 hour. Then intermediate 38 (516 mg, 2.93 mmol) was added and the reaction mixture was allowed to stir at room temperature for 30 minutes and at 100 ºC over a duration of 5 hours. The solvent was evaporated in high vacuum and the resulting residue was purified by column chromatography (silica gel, Petrol ether/EtOAc, 2:1) in order to obtain the product as a colourless solid. The solid was triturated with DCM, was separated by filtration and was washed with diethyl ether. Compound 37 was isolated as a colourless solid (51 mg, 5%). [00300] HPLC-MS [M+2H] 2+ 214.13; MP: 210-212 ºC; 1 H NMR (400 MHz, DMSO-d 6 ) δ 12.02 (bs, 1H), 8.84 (bs, 1H), 8.57 (bs, 1H), 8.02 (d, J = 9.2 Hz, 1H), 7.60 (bs, 1H), 7.34 – 7.24 (m, 2H), 7.15 (t, J = 7.8 Hz, 1H), 7.04 (dd, J = 7.8, 1.3 Hz, 1H), 6.61 (bs, 1H), 4.58 (dt, J = 13.5, 3.8 Hz, 2H), 3.91 (s, 3H), 3.49 (tt, J = 10.9, 3.9 Hz, 1H), 3.21 (ddd, J = 13.7, 11.5, 2.7 Hz, 2H), 2.23 (dd, J = 13.5, 3.6 Hz, 2H), 1.93 – 1.79 (m, 2H); 13 C NMR (101 MHz, DMSO-d 6 ) δ 182.29, 167.51, 156.52, 153.72, 150.03, 141.73, 139.22, 137.93, 128.37, 127.52, 123.92, 122.39, 119.93, 119.79, 114.88, 110.71, 109.77, 101.45, 56.13, 44.48, 34.36, 29.07. [00301] In an embodiment, the method of synthesizing compound 38 (3-(furan-2-yl)-5-(1-(8- methoxyquinolin-2-yl)piperidin-4-yl)-1,2,4-oxadiazole) is as follow: [00302] In an embodiment, preparation of Intermediate 39 ((Z)-N'-hydroxyfuran-2-carboximidamide) was performed. Hydroxylamine hydrochloride (440 mg, 6.4 mmol) was slowly added to a solution of nitrile starting material (500 mg, 5.3 mmol) in a mixture of MeOH (5 mL) and water (1 mL). Sodium hydrogencarbonate (530 mg, 6.4 mmol) was added and the mixture was allowed to stir at room temperature for 1h and at 85 ºC over a duration of 18 hours. The reaction mixture was evaporated in vacuum and the resulting residue was dissolved in DCM and was washed with water. The organic layer was dried over anhydrous sodium sulphate, was filtered and was evaporated in high vacuum to give Intermediate 39 as an oil (510 mg g, 75%). [00303] In an embodiment, preparation of compound 38 (3-(furan-2-yl)-5-(1-(8-methoxyquinolin-2- yl)piperidin-4-yl)-1,2,4-oxadiazole) was performed. CDI (600 mg, 3.7 mmol) was added to a solution of Intermediate 18 (700 mg, 2.5 mmol) in a mixture of PhMe (10 mL) and DMF (5 mL) and the reaction mixture was allowed to stir at room temperature over a duration of 1 hour. Then intermediate 39 (460 mg, 3.7 mmol) was added and the reaction mixture and it was allowed to stir at 90 ºC over a duration of 20 hours. The solvent was evaporated in high vacuum and the resulting residue was purified by column chromatography (silica gel, DCM/MeOH 2%). Compound 38 was isolated as a brown solid (430 mg, 45%). [00304] HPLC-MS [M+H] + 377.13; MP: 105-107ºC; 1 H NMR (500 MHz, DMSO-d 6 ) δ 8.00 (d, J = 9.2 Hz, 1H), 7.98 – 7.93 (m, 1H), 7.28 – 7.24 (m, 2H), 7.23 – 7.19 (m, 1H), 7.14 (t, J = 7.9 Hz, 1H), 7.03 (dd, J = 7.7, 1.2 Hz, 1H), 6.76 – 6.70 (m, 1H), 4.53 (dt, J = 13.5, 3.8 Hz, 2H), 3.92 (s, 3H), 3.44 (tt, J = 11.1, 4.0 Hz, 1H), 3.20 (ddd, J = 13.8, 11.5, 2.8 Hz, 2H), 2.19 (dd, J = 13.2, 3.8 Hz, 2H), 1.89 – 1.77 (m, 2H); 13 C NMR (126 MHz, DMSO-d 6 ) δ 182.39, 161.00, 156.53, 153.83, 146.70, 142.07, 139.36, 137.91, 124.00, 122.41, 119.86, 114.64, 110.66, 110.06, 56.29, 44.48, 34.28, 28.96. [00305] In an embodiment, the method of synthesizing compound 39 (5-(1-(8-methoxyquinolin-2- yl)piperidin-4-yl)-3-(6-methylpyridin-3-yl)-1,2,4-oxadiazole ) is as follow: [00306] In an embodiment, preparation of Intermediate 40 ((Z)-N'-hydroxy-6-methylnicotinimidamide) was performed. Hydroxylamine hydrochloride (340 mg, 5 mmol) was slowly added to a solution of nitrile starting material (500 mg, 4.2 mmol) in a mixture of MeOH (5 mL) and water (1 mL). Sodium hydrogencarbonate (420 mg, 5 mmol) was added and the mixture was allowed to stir at 85 ºC over a duration of 4 hours. The reaction mixture was evaporated in vacuum and the resulting residue was suspended in water and was filtered. Intermediate 40 was isolated as a colourless solid (480 mg, 75%). [00307] In an embodiment, preparation of compound 39 (5-(1-(8-methoxyquinolin-2-yl)piperidin-4-yl)-3- (6-methylpyridin-3-yl)-1,2,4-oxadiazole) was performed. CDI (690 mg, 4.2 mmol) was added to a solution of Intermediate 18 (800 mg, 2.8 mmol) in a mixture of PhMe (12 mL) and DMF (5.5 mL) and the reaction mixture was allowed to stir at room temperature over a duration of 1 hour. Then intermediate 40 (630 mg, 4.2 mmol) was added and the reaction mixture was allowed to stir at room temperature for 30 minutes and at 90 ºC over a duration of 2 hours. The solvent was evaporated in high vacuum and the resulting residue was recrystallized from Isop. Compound 39 was isolated as an off-white solid (600 mg, 53%). [00308] HPLC-MS [M+H] + 402.02; MP: 109-111 ºC; 1 H NMR (400 MHz, DMSO-d 6 ) δ 9.06 – 9.00 (m, 1H), 8.23 (dd, J = 8.1, 2.3 Hz, 1H), 8.02 (d, J = 9.1 Hz, 1H), 7.45 (d, J = 8.1 Hz, 1H), 7.33 – 7.24 (m, 2H), 7.14 (t, J = 7.8 Hz, 1H), 7.03 (dd, J = 7.7, 1.3 Hz, 1H), 4.57 (dt, J = 13.2, 3.7 Hz, 2H), 3.91 (s, 3H), 3.50 (tt, J = 11.2, 3.9 Hz, 1H), 3.20 (ddd, J = 13.7, 11.6, 2.7 Hz, 2H), 2.56 (s, 3H), 2.22 (dd, J = 12.9, 3.1 Hz, 2H), 1.92 – 1.77 (m, 2H); 13 C NMR (101 MHz, DMSO-d 6 ) δ 182.80, 166.27, 161.75, 156.49, 153.71, 147.57, 139.21, 137.93, 135.20, 124.08, 123.92, 122.40, 120.23, 119.79, 110.70, 109.77, 56.13, 44.44, 34.36, 29.01, 24.61. [00309] In an embodiment, the method of synthesizing compound 40 (tert-butyl ((1-(5-(5-(1-(8- methoxyquinolin-2-yl)piperidin-4-yl)-1,2,4-oxadiazol-3-yl)py ridin-2-yl)piperidin-4-yl)methyl)carbamate) is as follow: [00310] In an embodiment, preparation of compound 40 (tert-butyl ((1-(5-(5-(1-(8-methoxyquinolin-2- yl)piperidin-4-yl)-1,2,4-oxadiazol-3-yl)pyridin-2-yl)piperid in-4-yl)methyl)carbamate) was performed. Tert- Butyl (piperidin-4-ylmethyl)carbamate (1 g, 4.67 mmol) was added to a stirring dispersion of Compound 31 (200 mg, 0.47 mmol) and DIPEA (0.2 mL, 1.4 mmol) in 1,4-dioxane (6 mL) at room temperature. The mixture was allowed to stir at reflux over a duration of 20 hours. The solvent was evaporated in high vacuum and the product was purified by preparative TLC (silica gel, Petrol ether/EtOAc, 1:2). Compound 40 was isolated as a colourless solid (302 mg, 54%). [00311] HPLC-MS [M+H] + 600.36; MP: 130-133 ºC; 1 H NMR (400 MHz, CDCl 3 ) δ 8.84 (bs, 1H), 8.04 (dd, J = 9.0, 2.4 Hz, 1H), 7.89 (d, J = 9.1 Hz, 1H), 7.26 – 7.12 (m, 2H), 7.05 (d, J = 9.2 Hz, 1H), 6.96 (dd, J = 7.6, 1.4 Hz, 1H), 6.67 (d, J = 9.0 Hz, 1H), 4.65 (bs, 1H), 4.57 (dt, J = 13.6, 3.9 Hz, 2H), 4.44 (dt, J = 13.9, 2.9 Hz, 2H), 4.03 (s, 3H), 3.33 – 3.18 (m, 3H), 3.08 – 3.00 (m, 2H), 2.89 (td, J = 13.2, 12.8, 2.4 Hz, 2H), 2.27 (dt, J = 12.2, 3.7 Hz, 2H), 2.14 – 1.99 (m, 2H), 1.85 – 1.68 (m, 3H), 1.44 (s, 9H), 1.31 – 1.19 (m, 2H); 13 C NMR (101 MHz, CDCl 3 ) δ 181.03, 166.79, 159.98, 156.77, 156.05, 153.54, 147.92, 139.23, 137.68, 136.09, 123.96, 122.28, 119.45, 111.31, 110.05, 108.75, 106.09, 56.14, 46.03, 44.84, 36.97, 34.87, 29.32, 28.41. [00312] In an embodiment, the method of synthesizing compound 41 (tert-butyl ((1-(5-(5-(1-(8- methoxyquinolin-2-yl)piperidin-4-yl)-1,2,4-oxadiazol-3-yl)py ridin-2-yl)pyrrolidin-3-yl)methyl)carbamate) is as follow: [00313] In an embodiment, preparation of compound 41 (tert-butyl (tert-butyl ((1-(5-(5-(1-(8- methoxyquinolin-2-yl)piperidin-4-yl)-1,2,4-oxadiazol-3-yl)py ridin-2-yl)pyrrolidin-3-yl)methyl)carbamate) was performed.3-N-Boc-aminomethylpyrrolidine (700 mg, 3.56 mmol) was added to a stirring dispersion of Compound 31 (150 mg, 0.36 mmol) and DIPEA (0.1 mL, 0.72 mmol) in 1,4-dioxane (6 mL) at room temperature. The mixture was allowed to stir at reflux over a duration of 20 hours. The solvent was evaporated in high vacuum and the product was purified by column chromatography (silica gel, Petrol ether/EtOAc, 1:2). Compound 41 was isolated as a colourless solid (139 mg, 66%). [00314] HPLC-MS [M+H] + 586.31; MP: 105-107 ºC; 1 H NMR (400 MHz, CDCl 3 ) δ 8.87 – 8.81 (m, 1H), 8.04 (dd, J = 9.0, 2.4 Hz, 1H), 7.90 (d, J = 9.1 Hz, 1H), 7.26 – 7.12 (m, 2H), 7.05 (d, J = 9.2 Hz, 1H), 6.96 (dd, J = 7.6, 1.4 Hz, 1H), 6.40 (d, J = 8.8 Hz, 1H), 4.71 (bs, 1H), 4.58 (dt, J = 13.6, 3.9 Hz, 2H), 4.03 (s, 3H), 3.75 – 3.60 (m, 2H), 3.54 – 3.45 (m, 1H), 3.32 – 3.16 (m, 6H), 2.63 – 2.50 (m, 1H), 2.28 (dd, J = 13.5, 3.7 Hz, 2H), 2.19 – 2.03 (m, 3H), 1.86 – 1.72 (m, 1H), 1.45 (s, 9H); 13 C NMR (101 MHz, CDCl 3 ) δ 180.97, 167.01, 158.03, 156.78, 153.54, 148.22, 146.58, 139.23, 137.67, 135.66, 123.96, 122.27, 119.45, 110.70, 110.05, 108.74, 106.09, 56.14, 50.28, 46.25, 44.77, 43.15, 39.11, 34.87, 29.25, 28.99, 28.38. [00315] In an embodiment, the method of synthesizing compound 42 (1-(5-(5-(1-(8-methoxyquinolin-2- yl)piperidin-4-yl)-1,2,4-oxadiazol-3-yl)pyridin-2-yl)pyrroli din-3-yl)methanamine trifluoroacetate) is as follow: [00316] In an embodiment, preparation of compound 42 (tert-butyl (1-(5-(5-(1-(8-methoxyquinolin-2- yl)piperidin-4-yl)-1,2,4-oxadiazol-3-yl)pyridin-2-yl)pyrroli din-3-yl)methanamine trifluoroacetate) was performed. Trifluoroacetic acid (5 mL) was added to a stirring solution of Compound 41 (100 mg, 0.17 mmol) in EtOAc (1 mL). The mixture was allowed to stir at room temperature for 1 hour. The solvent was evaporated in high vacuum and the product was triturated with diethyl ether. Compound 42 was isolated as an off-white solid (95.7 mg, 97%). [00317] HPLC-MS [M+2H] 2+ 243.69; MP: 198-201 ºC; 1 H NMR (400 MHz, DMSO-d 6 ) δ 8.58 – 8.52 (m, 1H), 8.39 (d, J = 9.6 Hz, 1H), 8.31 (bs, 2H), 8.22 (dd, J = 9.2, 2.2 Hz, 1H), 7.63 (d, J = 9.6 Hz, 1H), 7.49 (dd, J = 7.8, 1.5 Hz, 1H), 7.46 – 7.33 (m, 2H), 6.90 (d, J = 9.2 Hz, 1H), 4.49 – 4.41 (m, 2H), 4.03 (s, 3H), 3.83 – 3.68 (m, 2H), 3.68 – 3.48 (m, 4H), 3.48 – 3.37 (m, 1H), 3.00 – 2.87 (m, 2H), 2.77 – 2.65 (m, 1H), 2.34 – 2.13 (m, 3H), 2.05 – 1.84 (m, 3H); 13 C NMR (101 MHz, DMSO-d 6 ) δ 181.93, 165.58, 158.52, 125.21, 122.55, 120.18, 113.27, 112.64, 110.65, 96.29, 56.83, 51.43, 47.56, 46.61, 41.07, 36.70, 33.21, 32.44, 30.56, 28.93, 28.79. [00318] In an embodiment, the method of synthesizing compound 43 ((1-(5-(5-(1-(8-methoxyquinolin-2- yl)piperidin-4-yl)-1,2,4-oxadiazol-3-yl)pyridin-2-yl)piperid in-4-yl)methanamine trifluoroacetate) is as follow: [00319] In an embodiment, preparation of compound 43 ((1-(5-(5-(1-(8-methoxyquinolin-2-yl)piperidin-4- yl)-1,2,4-oxadiazol-3-yl)pyridin-2-yl)piperidin-4-yl)methana mine trifluoroacetate) was performed. Trifluoroacetic acid (5 mL) was added to a stirring solution of Compound 40 (220 mg, 0.37 mmol) in EtOAc (1 mL). The mixture was allowed to stir at room temperature for 1 hour. The solvent was evaporated in high vacuum and the product was triturated with diethyl ether. Compound 43 was isolated as an off-white solid (280 mg, 99%). [00320] HPLC-MS [M+2H] 2+ 250.70; MP: 45-50 ºC; 1 H NMR (400 MHz, DMSO-d 6 ) δ 8.70 – 8.65 (m, 1H), 8.26 (d, J = 9.5 Hz, 1H), 8.01 (dd, J = 9.1, 2.4 Hz, 1H), 7.81 (bs, 2H), 7.51 (d, J = 9.5 Hz, 1H), 7.41 (dd, J = 7.9, 1.3 Hz, 1H), 7.32 (t, J = 7.9 Hz, 1H), 7.25 (d, J = 7.8 Hz, 1H), 7.01 (d, J = 9.1 Hz, 1H), 4.52 – 4.45 (m, 4H), 3.99 (s, 3H), 3.54 (tt, J = 11.0, 3.9 Hz, 1H), 3.46 – 3.34 (m, 2H), 2.99 – 2.87 (m, 2H), 2.81 – 2.70 (m, 2H), 2.25 (dd, J = 13.8, 3.8 Hz, 2H), 1.99 – 1.85 (m, 3H), 1.80 (dd, J = 13.6, 3.4 Hz, 2H), 1.25 – 1.12 (m, 2H); 13 C NMR (101 MHz, DMSO-d 6 ) δ 181.65, 166.41, 159.72, 158.87, 157.00, 147.17, 136.34, 132.72, 124.29, 123.01, 120.04, 117.67, 114.77, 112.36, 110.81, 107.33, 56.57, 45.86, 44.40, 44.06, 34.55, 33.61, 29.01, 28.90. [00321] In an embodiment, the method of synthesizing compound 44 (3-(6-methoxybenzo[d]thiazol-2-yl)- 5-(1-(8-methoxyquinolin-2-yl)piperidin-4-yl)-1,2,4-oxadiazol e) is as follow: In an embodiment, preparation of Intermediate 41 ((Z)-N'-hydroxy-6-methoxybenzo[d]thiazole-2- carboximidamide) was performed. Hydroxylamine hydrochloride (210 mg, 3.1 mmol) was slowly added to a solution of nitrile starting material (500 mg, 2.6 mmol) in a mixture of MeOH (5 mL) and water (1 mL). Sodium hydrogencarbonate (260 mg, 3.1 mmol) was added and the mixture was allowed to stir at 85 ºC over a duration of 3 hours. The reaction mixture was evaporated in vacuum and the resulting residue was suspended in water and was filtered. Intermediate 41 was isolated as a colourless solid (480 mg, 82%). [00322] In an embodiment, preparation of compound 44 (3-(6-methoxybenzo[d]thiazol-2-yl)-5-(1-(8- methoxyquinolin-2-yl)piperidin-4-yl)-1,2,4-oxadiazole) was performed. CDI (690 mg, 4.2 mmol) was added to a solution of Intermediate 18 (800 mg, 2.8 mmol) in a mixture of PhMe (12 mL) and DMF (5.5 mL) and the reaction mixture was allowed to stir at room temperature over a duration of 1 hour. Then intermediate 41 (930 mg, 4.2 mmol) was added and the reaction mixture was allowed to stir at room temperature for 30 minutes and at 90 ºC over a duration of 2 hours. The solvent was evaporated in high vacuum and the resulting residue was purified by column chromatography (silica gel, DCM/MeOH 2%) and Compound 44 was isolated pale yellow solid (80 mg, 6%). [00323] HPLC-MS [M+H] + 474.12; MP: 141-143 ºC; 1 H NMR (400 MHz, DMSO-d 6 ) δ 8.10 (d, J = 9.0 Hz, 1H), 8.02 (d, J = 9.2 Hz, 1H), 7.85 – 7.79 (m, 1H), 7.34 – 7.19 (m, 3H), 7.15 (t, J = 7.9 Hz, 1H), 7.04 (dd, J = 7.9, 1.3 Hz, 1H), 4.58 (dt, J = 13.5, 3.8 Hz, 2H), 3.91 (s, 3H), 3.88 (s, 3H), 3.54 (tt, J = 11.0, 3.9 Hz, 1H), 3.21 (ddd, J = 13.7, 11.5, 2.7 Hz, 2H), 2.25 (dd, J = 13.5, 3.7 Hz, 2H), 1.95 – 1.80 (m, 2H); 13 C NMR (101 MHz, DMSO- d 6 ) δ 183.51, 164.09, 159.16, 156.51, 153.73, 151.41, 148.05, 139.21, 137.93, 137.23, 125.17, 123.94, 123.79, 122.41, 119.79, 117.72, 110.70, 109.77, 105.13, 56.33, 56.13, 44.41, 34.40, 28.89. [00324] In an embodiment, the method of synthesizing compound 45 (5-(1-(8-methoxyquinolin-2- yl)piperidin-4-yl)-3-(thiophen-2-yl)-1,2,4-oxadiazole) is as follow: [00325] In an embodiment, preparation of Intermediate 42 ((Z)-N'-hydroxythiophene-2-carboximidamide) was performed. Hydroxylamine hydrochloride (380 mg, 5.5 mmol) was slowly added to a solution of nitrile starting material (500 mg, 4.5 mmol) in a mixture of MeOH (5 mL) and water (1 mL). Sodium hydrogencarbonate (460 mg, 5.5 mmol) was added and the mixture was allowed to stir at 85 ºC over a duration of 18 hours. The reaction mixture was evaporated in vacuum and the resulting residue was suspended in water and was filtered. Intermediate 42 was isolated as a colourless solid (224 mg, 35%). [00326] In an embodiment, preparation of compound 45 (5-(1-(8-methoxyquinolin-2-yl)piperidin-4-yl)-3- (thiophen-2-yl)-1,2,4-oxadiazole) was performed. CDI (420 mg, 2.6 mmol) was added to a solution of Intermediate 18 (500 mg, 1.7 mmol) in a mixture of PhMe (9 mL) and DMF (4 mL) and the reaction mixture was allowed to stir at room temperature over a duration of 1 hour. Then intermediate 42 (380 mg, 2.6 mmol) was added and the reaction mixture was allowed to stir at room temperature for 30 minutes and at 90 ºC over a duration of 2 hours. The solvent was evaporated in high vacuum and the product was recrystallized from Isop. Compound 45 was isolated as brown solid (400 mg, 60%). [00327] HPLC-MS [M+H] + 393.14; MP: 100-105 ºC; 1 H NMR (400 MHz, DMSO-d 6 ) δ 8.02 (d, J = 9.2 Hz, 1H), 7.91 – 7.76 (m, 2H), 7.33 – 7.22 (m, 3H), 7.15 (t, J = 7.8 Hz, 1H), 7.04 (dd, J = 7.8, 1.3 Hz, 1H), 4.56 (dt, J = 13.5, 3.8 Hz, 2H), 3.91 (s, 3H), 3.47 (tt, J = 11.2, 3.9 Hz, 1H), 3.18 (ddd, J = 13.8, 11.6, 2.7 Hz, 2H), 2.20 (dd, J = 13.3, 3.6 Hz, 2H), 1.90 – 1.75 (m, 2H); 13 C NMR (101 MHz, DMSO-d 6 ) δ 182.50, 164.05, 156.49, 153.71, 139.21, 137.93, 131.09, 130.29, 128.97, 127.95, 123.92, 122.39, 119.79, 110.71, 109.77, 56.13, 44.45, 34.32, 28.98. [00328] In an embodiment, the method of synthesizing compound 46 (4-(5-(5-(1-(8-methoxyquinolin-2- yl)piperidin-4-yl)-1,2,4-oxadiazol-3-yl)pyridin-2-yl)morphol ine) is as follow:
[00329] In an embodiment, preparation of compound 46 (54-(5-(5-(1-(8-methoxyquinolin-2-yl)piperidin- 4-yl)-1,2,4-oxadiazol-3-yl)pyridin-2-yl)morpholine) was performed. Morpholine (410 mg, 4.7 mmol) was added to a stirring dispersion of Compound 31 (200 mg, 0.47 mmol) and DIPEA (0.2 mL, 0.94 mmol) in 1,4-dioxane (10 mL) at room temperature. The mixture was allowed to stir at reflux over a duration of 20 hours. The solvent was evaporated in high vacuum and the product was purified by column chromatography (silica gel, Petrol ether/EtOAc, 2:1). Compound 46 was isolated as an off-white solid (138 mg, 62%). [00330] HPLC-MS [M+2H] 2+ 237.15; MP: 187-190 ºC; 1 H NMR (400 MHz, CDCl 3 ) δ 8.89 – 8.83 (m, 1H), 8.11 (dd, J = 8.9, 2.4 Hz, 1H), 7.97 (d, J = 9.3 Hz, 1H), 7.25 – 7.22 (m, 2H), 7.08 (d, J = 9.3 Hz, 1H), 7.05 – 7.00 (m, 1H), 6.68 (dd, J = 9.0, 0.8 Hz, 1H), 4.54 (dt, J = 13.7, 4.0 Hz, 2H), 4.03 (s, 3H), 3.83 (dd, J = 5.7, 4.1 Hz, 4H), 3.63 (dd, J = 5.7, 4.1 Hz, 4H), 3.43 – 3.38 (m, 2H), 3.32 (ddd, J = 10.7, 6.7, 4.0 Hz, 1H), 2.33 (dd, J = 13.6, 3.8 Hz, 2H), 2.19 – 2.04 (m, 2H); 13 C NMR (101 MHz, CDCl 3 ) δ 180.80, 166.61, 160.05, 155.54, 152.23, 147.54, 140.76, 139.33, 136.41, 123.43, 123.40, 119.38, 112.47, 110.56, 109.91, 106.17, 66.61, 56.19, 45.56, 45.18, 34.33, 29.10. [00331] In an embodiment, the method of synthesizing compound 47 (3-(5-(1-(8-methoxyquinolin-2- yl)piperidin-4-yl)-1,2,4-oxadiazol-3-yl)aniline hydrochloride) is as follow: [00332] In an embodiment, preparation of Intermediate 43 (Z)-3-amino-N'-hydroxybenzimidamide) was performed. Hydroxylamine hydrochloride (1.4 g, 20 mmol) was slowly added to a solution of nitrile starting material (2 g, 17 mmol) in a mixture of MeOH (20 mL) and water (10 mL). Sodium hydrogencarbonate (1.7 g, 20 mmol) was added and the mixture was allowed to stir at 60 ºC over a duration of 2 hours. The reaction mixture was evaporated in vacuum and the resulting residue was suspended in water and was filtered. Intermediate 43 was isolated as a pale yellow solid (1.87g, 73%). [00333] In an embodiment, preparation of compound 47 (3-(5-(1-(8-methoxyquinolin-2-yl)piperidin-4-yl)- 1,2,4-oxadiazol-3-yl)aniline hydrochloride) was performed. CDI (615 mg, 3.77 mmol) was added to a solution of Intermediate 18 (900 mg, 3.1 mmol) in a mixture of PhMe (10 mL) and DMF (2 mL) and the reaction mixture was allowed to stir at room temperature over a duration of 1 hour. Then intermediate 43 (570 mg, 3.77 mmol) was added and the reaction mixture was allowed to stir at room temperature for 30 minutes and at 90 ºC over a duration of 5 hours. The solvent was evaporated in high vacuum and the resulting residue was purified by column chromatography (silica gel, Petrol ether 1:2). The resulting oil was dissolved in EtOAc (5 mL) and a 2M solution of hydrochloric acid in diethyl ether (1 mL) was added dropwise a 0 ºC. The precipitate was separated by filtration and was washed with cold diethyl ether. Compound 47 was isolated as a pale brown solid (100 mg, 10%). [00334] HPLC-MS [M+H] + 402.20; MP: 195-202 ºC; 1 H NMR (400 MHz, DMSO-d 6 ) δ 8.41 (d, J = 9.6 Hz, 1H), 7.90 (bs, 1H), 7.87 (d, J = 7.9 Hz, 1H), 7.66 (d, J = 9.6 Hz, 1H), 7.60 (t, J = 7.9 Hz, 1H), 7.49 (dd, J = 16.5, 8.0 Hz, 2H), 7.43 (t, J = 7.9 Hz, 1H), 7.39 (d, J = 8.0 Hz, 1H), 4.44 (dt, J = 14.0, 3.9 Hz, 2H), 4.04 (s, 3H), 3.82 (bs, 2H), 3.65 (tt, J = 10.9, 4.1 Hz, 1H), 3.60 – 3.54 (m, 2H), 2.32 (dd, J = 13.9, 3.9 Hz, 2H), 2.06 – 1.99 (m, 2H); 13 C NMR (101 MHz, DMSO-d 6 ) δ 182.22, 167.38, 153.07, 148.92, 142.39, 131.18, 131.11, 127.78, 127.72, 125.41, 125.10, 124.54, 122.48, 120.40, 120.22, 113.47, 112.81, 56.90, 46.74, 33.17, 28.91. [00335] In an embodiment, the method of synthesizing compound 48 (3-(6-methoxypyridin-3-yl)-5-(1-(8- methoxyquinolin-2-yl)piperidin-4-yl)-1,2,4-oxadiazole) is as follow: [00336] In an embodiment, preparation of Intermediate 44 ((Z)-N'-hydroxy-6-methoxynicotinimidamide) was performed. Hydroxylamine hydrochloride (300 mg, 4.4 mmol) was slowly added to a solution of nitrile starting material (500 mg, 3.7 mmol) in a mixture of MeOH (5 mL) and water (1 mL). Sodium hydrogencarbonate (360 mg, 4.4 mmol) was added and the mixture was allowed to stir at 85 ºC over a duration of 2 hours. The reaction mixture was evaporated in vacuum and the resulting residue was suspended in water and was filtered. Intermediate 44 was isolated as a colourless solid (344 mg, 54%). [00337] In an embodiment, preparation of compound 48 (3-(6-methoxypyridin-3-yl)-5-(1-(8- methoxyquinolin-2-yl)piperidin-4-yl)-1,2,4-oxadiazole) was performed. CDI (330 mg, 2 mmol) was added to a solution of Intermediate 18 (380 mg, 1.3 mmol) in a mixture of PhMe (7 mL) and DMF (3 mL) and the reaction mixture was allowed to stir at room temperature over a duration of 1 hour. Then intermediate 44 (330 mg, 2 mmol) was added and the reaction mixture was allowed to stir at 80 ºC over a duration of24 hours. The solvent was evaporated in high vacuum and the product was recrystallized from Isop. Compound 48 was isolated as a pale brown solid (294 mg, 54%). [00338] HPLC-MS [M+H] + 418.23; MP: 97-101 ºC; 1 H NMR (400 MHz, DMSO-d 6 ) δ 8.82 – 8.75 (m, 1H), 8.23 (dd, J = 8.7, 2.4 Hz, 1H), 8.02 (d, J = 9.2 Hz, 1H), 7.33 – 7.24 (m, 2H), 7.14 (t, J = 7.8 Hz, 1H), 7.09 – 6.96 (m, 2H), 4.57 (dt, J = 13.5, 3.8 Hz, 2H), 3.93 (s, 3H), 3.91 (s, 3H), 3.48 (tt, J = 11.2, 3.9 Hz, 1H), 3.19 (ddd, J = 13.7, 11.6, 2.7 Hz, 2H), 2.21 (dd, J = 13.4, 3.8 Hz, 2H), 1.91 – 1.76 (m, 2H); 13 C NMR (101 MHz, DMSO-d 6 ) δ 182.58, 166.06, 165.80, 156.48, 153.71, 146.60, 139.21, 137.99, 137.93, 123.91, 122.39, 119.79, 116.67, 111.81, 110.69, 109.77, 56.12, 54.21, 44.44, 34.36, 29.03. [00339] In an embodiment, the method of synthesizing compound 49 (3-(5-fluoropyridin-3-yl)-5-(1-(8- methoxyquinolin-2-yl)piperidin-4-yl)-1,2,4-oxadiazole) is as follow: [00340] In an embodiment, preparation of Intermediate 45 ((Z)-5-fluoro-N'-hydroxynicotinimidamide) was performed. Hydroxylamine hydrochloride (300 mg, 4.9 mmol) was slowly added to a solution of nitrile starting material (500 mg, 4 mmol) in a mixture of MeOH (5 mL) and water (1 mL). Sodium hydrogencarbonate (400 mg, 4.9 mmol) was added and the mixture was allowed to stir at 85 ºC over a duration of 2 hours. The reaction mixture was evaporated in vacuum and the resulting residue was suspended in water and was filtered. Intermediate 45 was isolated as a colourless solid (400 mg, 65%). [00341] In an embodiment, preparation of compound 49 (3-(5-fluoropyridin-3-yl)-5-(1-(8- methoxyquinolin-2-yl)piperidin-4-yl)-1,2,4-oxadiazole) was performed. CDI (400 mg, 2.5 mmol) was added to a solution of Intermediate 18 (470 mg, 1.6 mmol) in a mixture of PhMe (9 mL) and DMF (4 mL) and the reaction mixture was allowed to stir at room temperature over a duration of 1 hour. Then intermediate 45 (380 mg, 2.5 mmol) was added and the reaction mixture was allowed to stir at 80 ºC over a duration of 24 hours. The solvent was evaporated in high vacuum and the product was recrystallized from Isop. Compound 49 was isolated as an off-white solid (414 mg, 62%). [00342] HPLC-MS [M+H] + 406.21; MP: 143-152 ºC; 1 H NMR (400 MHz, DMSO-d 6 ) δ 9.07 – 9.01 (m, 1H), 8.87 – 8.79 (m, 1H), 8.27 – 8.19 (m, 1H), 8.02 (d, J = 9.2 Hz, 1H), 7.34 – 7.24 (m, 2H), 7.14 (t, J = 7.8 Hz, 1H), 7.03 (dd, J = 7.7, 1.3 Hz, 1H), 4.57 (dt, J = 13.5, 3.8 Hz, 2H), 3.91 (s, 3H), 3.53 (tt, J = 11.1, 3.9 Hz, 1H), 3.21 (ddd, J = 13.7, 11.5, 2.7 Hz, 2H), 2.22 (dd, J = 13.4, 3.7 Hz, 2H), 1.94 – 1.78 (m, 2H); 13 C NMR (101 MHz, DMSO- d 6 ) δ 183.26, 165.39, 160.68, 156.48, 153.71, 144.38, 141.29, 139.21, 137.94, 123.92, 122.40, 121.76, 119.79, 110.70, 109.77, 56.13, 44.41, 34.36, 28.95. [00343] In an embodiment, the method of synthesizing compound 50 (5-(1-(8-methoxyquinolin-2- yl)piperidin-4-yl)-3-(6-(pyrrolidin-1-yl)pyridin-3-yl)-1,2,4 -oxadiazole hydrochloride) is as follow: [00344] In an embodiment, preparation of Intermediate 46 ((Z)-N'-hydroxy-6-(pyrrolidin-1- yl)nicotinimidamide) was performed. Hydroxylamine hydrochloride (610 mg, 8.7 mmol) was slowly added to a solution of nitrile starting material (1 g, 5.8 mmol) in a mixture of MeOH (10 mL) and water (2 mL). Sodium hydrogencarbonate (731 mg, 8.7 mmol) was added and the mixture was allowed to stir at 85 ºC over a duration of 2 hours. The reaction mixture was evaporated in vacuum and the resulting residue was suspended in water and was filtered. Intermediate 46 was isolated as a colourless solid (1.07 g, 89%). [00345] In an embodiment, preparation of compound 50 (5-(1-(8-methoxyquinolin-2-yl)piperidin-4-yl)-3- (6-(pyrrolidin-1-yl)pyridin-3-yl)-1,2,4-oxadiazole hydrochloride) was performed. CDI (592 mg, 3.64 mmol) was added to a solution of Intermediate 18 (867 mg, 3.03 mmol) in a mixture of PhMe (10 mL) and DMF (2 mL) and the reaction mixture was allowed to stir at room temperature over a duration of 1 hour. Then intermediate 46 (750 mg, 3.64 mmol) was added and the reaction mixture was allowed to stir at room temperature for 30 minutes and at 80 ºC over a duration of 2 hours. The solvent was evaporated in high vacuum and the product was purified by column chromatography (silica gel, Petrol ether/EtOAc, 1:2). The resulting oil was dissolved in EtOAc (5 mL) and a 2M solution of hydrochloric acid in diethyl ether (1 mL) was added dropwise a 0 ºC. The precipitate was separated by filtration and was washed with cold diethyl ether. Compound 50 was isolated as a yellow solid (212 mg, 14%). [00346] HPLC-MS [M+2H] 2+ 229.22; MP: 139-143 ºC; 1 H NMR (400 MHz, DMSO-d 6 ) δ 8.61 – 8.55 (m, 1H), 8.22 (d, J = 9.4 Hz, 1H), 8.11 (dd, J = 9.1, 2.3 Hz, 1H), 7.47 (d, J = 9.4 Hz, 1H), 7.39 (dd, J = 8.0, 1.3 Hz, 1H), 7.29 (t, J = 7.9 Hz, 1H), 7.22 (d, J = 7.8 Hz, 1H), 6.80 (d, J = 9.1 Hz, 1H), 4.53 – 4.47 (m, 2H), 3.98 (s, 3H), 3.57 – 3.47 (m, 5H), 3.43 – 3.32 (m, 2H), 2.30 – 2.19 (m, 2H), 2.01 – 1.88 (m, 6H); 13 C NMR (101 MHz, DMSO-d 6 ) δ 181.92, 180.45, 166.01, 157.85, 151.88, 136.89, 126.77, 125.86, 123.17, 120.00, 110.20, 56.51, 47.80, 45.62, 33.74, 29.00, 25.32. [00347] In an embodiment, the preferred compounds of general formula I are as follows: 5-(1-(8-methoxyquinolin-2-yl)piperidin-4-yl)-3-(4-(trifluoro methoxy)phenyl)-1,2,4-oxadiazole; 5-(1-(8-methoxyquinolin-2-yl)piperidin-4-yl)-3-(4-(trifluoro methyl)phenyl)-1,2,4-oxadiazole hydrochloride; 3-(3,5-dimethoxyphenyl)-5-(1-(8-methoxyquinolin-2-yl)piperid in-4-yl)-1,2,4-oxadiazole; 5-(1-(8-methoxyquinolin-2-yl)piperidin-4-yl)-3-(3-(trifluoro methyl)phenyl)-1,2,4-oxadiazole; 5-(1-(8-methoxyquinolin-2-yl)piperidin-4-yl)-3-(pyridin-3-yl )-1,2,4-oxadiazole hydrochloride; 5-(1-(8-methoxyquinolin-2-yl)piperidin-4-yl)-3-(6-(trifluoro methyl)pyridin-3-yl)-1,2,4-oxadiazole; 5-(1-(8-chloroquinolin-2-yl)piperidin-4-yl)-3-(pyridin-3-yl) -1,2,4-oxadiazole hydrochloride; 5-(1-(6-methoxyquinolin-2-yl)piperidin-4-yl)-3-(pyridin-3-yl )-1,2,4-oxadiazole; 4-(5-(1-(8-methoxyquinolin-2-yl)piperidin-4-yl)-1,2,4-oxadia zol-3-yl)phenol; 3-(pyridin-3-yl)-5-(1-(6-(pyridin-4-yl)quinolin-2-yl)piperid in-4-yl)-1,2,4-oxadiazole; 3-(6-chloropyridin-3-yl)-5-(1-(8-methoxyquinolin-2-yl)piperi din-4-yl)-1,2,4-oxadiazole hydrochloride; 5-(1-(8-methoxyquinolin-2-yl)piperidin-4-yl)-3-(6-(piperidin -1-yl)pyridin-3-yl)-1,2,4-oxadiazole; 5-(1-(8-methoxyquinolin-2-yl)piperidin-4-yl)-3-(6-(piperazin -1-yl)pyridin-3-yl)-1,2,4-oxadiazole; 2-((5-(5-(1-(8-methoxyquinolin-2-yl)piperidin-4-yl)-1,2,4-ox adiazol-3-yl)pyridin-2-yl)amino)ethan-1-ol hydrochloride; 5-(1-(8-methoxyquinolin-2-yl)piperidin-4-yl)-3-(6-(pyrrolidi n-1-yl)pyridin-3-yl)-1,2,4-oxadiazole hydrochloride; or a pharmaceutically acceptable salt, hydrate, solvate, N-oxide, stereoisomer, stereoisomer, in particular diastereoisomer, enantiomer or atropisomers, or mixtures thereof, polymorph or ester thereof. Example 2 [00348] In an embodiment, in vitro cytotoxicity assay was carried out. In vitro cytotoxicity assay was performed in HepG2 cell line using a tetrazolium reduction assay for cell viability evaluation (MTS reduction as described by Cory A. et al (Cancer Commun.1991, 3 (7), 207-212)). The assay was performed in 96-well plates for 48 h at 37 ºC and 5% CO 2 in incubation medium (low glucose DMEM with Glutamax, 10% FBS, 1% Pen/Strep and DMSO). Cells were exposed to 8 different compound concentrations in successive dilutions (usually, base 2), plus a positive control (a compound in a concentration known to decrease cell viability above 50%) and a negative control (incubation medium). Six replicate wells were assayed for each condition. Compound stock solutions were prepared in DMSO at 20 mM, whenever possible, filter sterilized, aliquoted and stored at – 20 ºC. The maximum compound concentrations tested depend on its solubility in incubation medium, and on the maximum DMSO percentage allowable without loss of cell viability. At the end of the incubation period, tetrazolium reagent was added (CellTiter 96 ® AQ ueous Solution from Promega); cells were incubated for another 3 hours in order to promote tetrazolium reduction to formazan by viable cells. The amount of soluble formazan produced was evaluated by 490 nm absorbance reading in a spectrophotometer plate reader. The average absorbance from the negative control wells corresponded to 100% cell viability; the absorbance obtained from each test condition were then transformed into a cell viability percentage – these results were plotted against compound concentration and a non-linear regression fit was made. Whenever possible, IC50 was calculated as the concentration of compound that reduces cell viability by 50%. Example 3 [00349] In an embodiment, Mycobacterium tuberculosis susceptibility assay REMA was carried out. M. tuberculosis susceptibility was accessed by exposing susceptible H37Rv M. tuberculosis, in particular M. tuberculosis strain ATCC 25618 (for detail https://www.uniprot.org/taxonomy/83332, or order in https://www.szabo-scandic.com/en/recombinant-mycobacterium-t uberculosis-probable-cutinase- rv1984c-rv1984c), to the different compounds and evaluating its growth inhibition by REMA (resazurin microtiter assay) method based on Palomino JC et al (Mycobacterium tuberculosis Antimicrob. Agents Chemother. 2002, 46, 8, 2720-2722). The assay was performed in 96well plates for 6 days at 37 ºC in Middlebrook 7H9 medium. Cells were exposed to 8 different compound concentrations in two-fold serial dilutions; incubation medium was used as negative control and 2 positive controls were accessed: Rifampicin in a concentration known to inhibit growth and Moxifloxacin in 8 different concentrations, from no growth inhibition to full growth inhibition. Compound stock solutions were prepared in DMSO in a concentration at least 40X higher than the maximum concentration tested. At the end of the incubation period, resazurin was added and cells were incubated for another 2 days in order to promote resazurin colour change from blue to pink every time growth as occurred. Colours were recorded and the lowest concentration in which no colour change was observed (the last blue well) was assumed to be the minimum inhibitory concentration (MIC) for that compound in M. tuberculosis. Example 4 [00350] In an embodiment, metabolic stability assay was carried out. Metabolic stability was assessed by incubating test compounds in 96-well plates in 5 aliquots of 40 μL each (one for each time point) in liver microsomal incubation medium. This medium contained MgCl2 (3.3 mM), NADPН- cofactor system (NADPH (3 mM), glucose-6-phosphate (5.3 mM), glucose-6-phosphate dehydrogenase (0.67 units/ml)) and 0.42 mg of liver microsomal protein per ml in phosphate buffer (100 mM, pH 7.4). Control incubations were performed replacing the NADPH-cofactor system by phosphate buffer. Test compounds (1 μM, final solvent concentration 1.6 %) were incubated with microsomes at 37 ºC and 100 rpm orbital shaking. Imipramine and Propranolol were incubated in parallel as reference compounds. Each reaction was performed in duplicate. Five time points over a duration 60 minutes were analysed. The reactions were stopped by adding 12 volumes of 90% acetonitrile in water to incubation aliquots, followed by protein sedimentation by centrifugation. Supernatants were analysed using a Shimadzu VP HPLC system with a reverse phase HPLC column, coupled with tandem mass spectrometer API 3000 (PE Sciex). The TurboIonSpray source was used in both positive and negative ion modes. Acquisition and analysis of the data were performed using Analyst 1.5.2 software (PE Sciex). The elimination constant (k el ), half-life (t 1/2 ) and intrinsic clearance (Clint) were determined in plot of ln(AUC) versus time, using linear regression analysis for each test and reference compound. Example 5 [00351] In an embodiment, distribution coefficient (LogD) determination assay was carried out. Test compounds were incubated in Eppendorf-type polypropylene microtubes in triplicates: a 5 μL aliquot of a 10 mM DMSO stock of each test compound were added into the previously mutually saturated mixture containing 500 μL of phosphate buffer saline (pH 7.4) and 500 μL of octanol. The solution was allowed to mix in a rotator for 1 hour at 30 rpm. Phase separation was assured by centrifugation. The octanol phase was diluted 100-fold with 40% acetonitrile in water for analysis, and aqueous phase was analysed without dilution. Mebendazole was used as a reference compound. All samples (both phases) were analysed in a Shimadzu VP HPLC system with a reverse phase column, coupled with tandem mass spectrometer API 3000 (PE Sciex). The TurboIonSpray ion source was used in positive ion mode. Acquisition and analysis of the data were performed using Analyst 1.5.2 software. Distribution coefficients of the tested compounds were calculated as the logarithm of the partition ratios (D) in both solvents, according to the equation below. w here: S O – peak area of the compound in octanol phase S P – peak area of the compound in phosphate buffer saline phase Example 6 [00352] In an embodiment, pKa determination assay was carried out. The tendency of a compound to donate a proton is measured as its acid ionization constant (dissociation constant), or Ka. A more practical scale of representing acidity is pKa which is the negative logarithm of the Ka (pKa = -log Ka). The pKa determinations of the test compounds and 3 reference compounds were assessed by potentiometric titration, in accordance with the technical protocols for pKa measurement provided by Pion Inc. and Sirius Analytical Inc. Briefly, compounds pKa were determined by pH-metric method based on potentiometric acid-base titration at 25 ºC. The test and reference compounds were dissolved in acidified MeOH-water (1:4) solution of NaCl (150 mM, pH 2) and slowly titrated with 10 mM NaOH MeOH-water (1:4) solution. The recorded pH of the solution as a function of NaOH volume used during the titration were used to construct the titration curve. Titration of acidified NaCl solution in absence of any compound was used for blank plotting. Buffering capacity was calculated in each point of titration curve as the ratio of the NaOH flow (constant) to the pH rise velocity. The pKa value is determined from resulting plot of buffering capacity versus pH as the maximum of buffering capacity. pH-Metric method allows to measure pKa’s in range between 2 and 12. Acquisition and analysis of the data were performed using SmartLoggerII1.0.14 software (Beckman Coulter). Data analysis was done using GraphPad Prism 5.01 and Excel 2010 software. Example 7 [00353] In an embodiment, stability in human plasma (PS) assay was carried out. Test compounds (1 μM, final DMSO concentration 1%) were incubated in 5 aliquots of 70 μL each (one for each time point), in duplicates, at 37 ºC with 100 rpm orbital shaking. Five time points over a duration 120 minutes have been analysed. Two reference compounds were analysed in parallel. The reactions were stopped by the addition of 420 μL of acetonitrile-water mixture (90:10) and subsequent plasma proteins sedimentation were achieved by centrifugation. Supernatants were analysed in a Shimadzu VP HPLC system with a reverse phase column, coupled with a tandem mass spectrometer API 3000 (PE Sciex). Both the positive and negative ion modes of the TurboIonSpray ion source were used. Acquisition and analysis of the data were performed using Analyst 1.5.2 software (PE Sciex). The percentage of the test compounds remaining after incubation in plasma and their half-lives (T1/2) were calculated. Example 8 [00354] In an embodiment, human plasma protein binding (PPB) assay was carried out. The assay was performed in a multiple-use 96-well dialysis unit (HTD96b dialyzer). Each individual well unit consisted of 2 chambers separated by a vertically aligned dialysis membrane of predetermined pore size (MWCO 12- 14 kDa).120 μl of non-diluted plasma spiked with the compound (1 μM, 1% final DMSO concentration) was added to one chamber and the same volume of phosphate buffer saline pH 7.4 to the other chamber. HTD96b dialyzer was covered with adhesive sealing film and incubated at 37 ºC and 100 rpm orbital shaking for 5 hours. Verapamil was also evaluated in parallel as reference compound. For sample preparation, an aliquot of the content of each chamber was mixed with the same volume of the blank opposite matrix. In order to define non-specific loss of the compound during this assay, standard solution was created by mixing an aliquot of spiked plasma with blank buffer without dialysis. Samples were diluted 10-fold with 100% acetonitrile with subsequent plasma proteins sedimentation by centrifugation. Supernatants were analysed using a Shimadzu VP HPLC system with a reverse phase column, coupled with a tandem mass spectrometer API 3000 (PE Sciex). The both positive and negative ion modes of the TurboIonSpray ion source were used. Acquisition and analysis of the data were performed using Analyst 1.5.2 software (PE Sciex). [00355] The percentage of plasma protein bounded compound and its recovery were calculated using the equations below: Peak area in buffer Protein binding = 1 - - 100% Peak area in plasma Peak area in buffer + Peak area in plasma Recovery = - 100% Peak area in standard solution [00356] The percentage of plasma protein bounded compound and its recovery were calculated using the values obtained for each compound in the quantification of the 3 samples (in buffer, plasma and standard solution). Example 9 [00357] In an embodiment, PAMPA assay was carried. All steps of PAMPA assay were carried out according to pION Inc. PAMPA Explorer™ Manual. The main principle of the assay is the compound incubation in the donor chamber with aqueous buffer, which is separated from the acceptor chamber, with another buffer, by a phospholipid or hydrocarbon membrane fixed on a filter support. After the test, concentrations in the corresponding donor and acceptor chambers are measured and permeability is calculated. GIT model was simulated using GIT-0 phospholipid mix. Verapamil and quinidine (high permeability) and ranitidine (low permeability) were used as reference compounds. All compounds were tested in quadruplicates. Prisma HT buffer (pH 7.4) containing 50 μM test compound (final 0.5% DMSO concentration) was added into the donor chamber. Acceptor Sink Buffer was added into each acceptor chamber. Incubation was done at room temperature for 4 hours without stirring. After incubation, aliquots from both chambers were transferred to optic UV-Vis plates and absorbance was recorded in the range of 202-500 nm in 4 nm steps. Compounds with low UV-Vis signal were evaluated by LC-MS/MS (using a Shimadzu VP HPLC system with a reverse phase HPLC column, coupled with tandem mass spectrometer API 3000 (PE Sciex) and TurboIonSpray ion source used in positive ion mode; acquisition and analysis of the data were performed using Analyst 1.5.2 software (PE Sciex)). [00358] The apparent permeability coefficient was calculated using the formula below. [00359] The apparent permeability coefficient was calculated for each compound (logP app ). [00360] In an embodiment, the compounds of the present disclosure, when tested in cytotoxicity assay, typically have IC50 value not less than 50 µM. [00361] In an embodiment, compounds of the disclosure, when tested in susceptibility assay described in example 3 may typically have MIC lower than 31.25 µM. Compounds of the disclosure when tested in assay described in example 3 may have MIC between 1.95 µM and 31.25 µM. [00362] In an embodiment, the compounds of the present disclosure were tested in assays outlined in examples 2 and 3 as described above. Table 1 shows the results obtained: [00363] Table 1 - REMA and IC 50 results for selected compounds [00364] In Table 1, the results of REMA and cytotoxicity are set out as follows: [00365] Table 2 –REMA and IC 50 results for selected the compounds [00366] In the table 2, the results of REMA and cytotoxicity are set out as follows: [00367] In an embodiment, the compounds of the present disclosure have been shown to inhibit the growth of Mycobacterium tuberculosis in a standard REMA assay (Palomino JC et al, Mycobacterium tuberculosis Antimicrob. Agents Chemother. 2002, 46, 8, 2720-2722) with minimum inhibitory concentration (MIC) of not more than 31.5 µM. Surprisingly, the compounds of the present disclosure presented MIC not more than 15.6 µM. Even more surprising, the embodiments for better results of the present disclosure have MIC of not more than 7.8 µM. The compounds of the disclosure have also been found to be non-cytotoxic for HepG2 cell line, metabolically stable in human microsomes, stable in plasma and relatively permeable under gastrointestinal tract parallel artificial membrane. LogD and pKa, have been described. The compounds disclosed are promising antimycobacterial agents. [00368] In an embodiment, the compounds of the disclosure were tested in assay outlined in example 4 as described above and the following results were obtained. [00369] Table 3 – Cl int and t 1/2 results for selected compound n.d. = not determined [00370] In an embodiment, the compounds of the disclosure were tested in assay outlined in example 5, 6, 7, 8 and 9 as described above and the following results were obtained: [00371] Table 4 – Further biological data for selected compound n.d.-Not determined. [00372] The term "comprising" whenever used in this document is intended to indicate the presence of stated features, integers, steps, components, but not to preclude the presence or addition of one or more other features, integers, steps, components or groups thereof. [00373] It will be appreciated by those of ordinary skill in the art that unless otherwise indicated herein, the particular sequence of steps described is illustrative only and can be varied without departing from the disclosure. Thus, unless otherwise stated the steps described are so unordered meaning that, when possible, the steps can be performed in any convenient or desirable order. [00374] The disclosure should not be seen in any way restricted to the embodiments described and a person with ordinary skill in the art will foresee many possibilities to modifications thereof. The embodiments described above are combinable. [00375] The following claims further set out particular embodiments of the disclosure.